Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | RAD52 | P43351 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | PABPC1 | P11940 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | S1PR1 | P21453 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | AHR | P35869 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.67 |
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | PLK1 | P53350 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11552380 | 0.99 | MEN1 (0.98) | MEN1KMT2APOLBRAD52MAPT | |
| SCHEMBL14557199 | 0.92 | MEN1 (0.85) | MEN1KMT2APOLBRAD52MAPT | |
| SCHEMBL11441512 | 0.91 | MEN1 (0.83) | MEN1KMT2APOLBRAD52MAPT | |
| SCHEMBL10340131 | 0.90 | MEN1 (0.82) | MEN1KMT2APOLBRAD52MAPT | |
| Hydrochloric Acid SCHEMBL10898438 | 0.89 | MEN1 (0.80) | MEN1KMT2APOLBRAD52MAPT | |
| SCHEMBL10340125 | 0.89 | MEN1 (0.80) | MEN1KMT2APOLBRAD52MAPT | |
| SCHEMBL9501871 | 0.88 | MEN1 (0.79) | MEN1KMT2APOLBRAD52MAPT | |
| SCHEMBL3857829 | 0.86 | KDM4E (0.75) | MEN1KMT2APOLBRAD52MAPT | |
| SCHEMBL11447428 | 0.84 | PABPC1 (0.73) | MEN1KMT2APOLBRAD52MAPT | |
| SCHEMBL9017063 | 0.84 | MEN1 (0.72) | MEN1KMT2APOLBRAD52MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2463 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM | 2023-02-09 | — | — | US | claimed |
| US-20210205389-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | CHANG GUNG MEDICAL FOUND KEELUNG CHANG GUNG MEMORIAL HOSPITAL (TW) | 2021-07-08 | — | — | US | claimed |
| US-10953059-B2 | Methods and compositions for treating non-small cell lung cancer | CHANG GUNG MEDICAL FOUNDATION KEELUNG CHANG GUNG MEMORIAL HOSPITAL (TW) | 2021-03-23 | — | — | US | claimed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | claimed |
| CN-108289922-A | Therapeutic methods and compositions for treating non-small cell lung cancer | 友杏生技医药股份有限公司 | 2018-07-17 | — | — | CN | claimed |
| EP-3310174-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | OP NANO CO., LTD. (TW) | 2018-04-25 | — | — | EP | claimed |
| WO-2017190059-A1 | STABILIZING PROINSULIN MONOMERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-02 | — | — | WO | claimed |
| WO-2016197012-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | ORIENT PHARMA INC. (US) | 2016-12-08 | — | — | WO | claimed |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | TEXAS TECH UNIVERSITY SYSTEM | 2016-12-01 | — | — | US | claimed |
| WO-2015120254-A1 | DISULFIRAM COMPOSITIONS AND TREATMENTS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2015-08-13 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | JACOB GARY S | 2006-05-18 | — | — | US | claimed |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12612425-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2026-04-28 | — | — | US | disclosed |
| US-12595262-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12583871-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-12552826-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4673747-A1 | MEANS AND METHODS FOR DIAGNOSING CANCER AND/OR AN ACUTE INFLAMMATORY DISEASE | CARCIMUN BIOTECH GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-12516321-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2026-01-01 | — | — | US | disclosed |
| EP-3758715-B1 | AGENTS INHIBITING P-SELECTIN EXPRESSION AND/OR ACTIVITY FOR USE FOR INHIBITING EPITHELIAL CELL PROLIFERATION IN THE TREATMENT OF PRIMARY CANCER | GILLIES PETER (AU) | 2025-12-03 | — | — | EP | disclosed |
| US-12486503-B2 | Short interfering nucleic acid (siNA) compositions | SIRNA THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2025244963-A1 | ECTEINASCIDIN DERIVATIVES AND METHODS OF USE THEREOF AS ANTITUMOR AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4630001-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12441730-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3706747-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608398-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-3525785-B1 | KDM5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025136841-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12329766-B2 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4552697-A2 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025096952-A1 | SCAFFOLDS AND SCAFFOLD HOLDERS FOR TISSUE ENGINEERING | UNIVERSITY OF CONNECTICUT (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-3514151-B1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| EP-3833668-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250059220-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4076452-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12173026-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-12-24 | — | — | US | disclosed |
| EP-3240543-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-3240542-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-12122834-B2 | Anti-PD-1 antibodies | MERCK SHARP & DOHME LLC (US) | 2024-10-22 | — | — | US | disclosed |
| US-12103930-B2 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2024-10-01 | — | — | US | disclosed |
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024180169-A1 | MEANS AND METHODS FOR DIAGNOSING CANCER AND/OR AN ACUTE INFLAMMATORY DISEASE | CARCIMUN BIOTECH GMBH (DE) | 2024-09-06 | — | — | WO | disclosed |
| US-20240287515-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA) | BANK OF AMERICA, N.A. | 2024-08-29 | — | — | US | disclosed |
| US-20240247271-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2024-07-25 | — | — | US | disclosed |
| WO-2024123585-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11993602-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-05-28 | — | — | US | disclosed |
| US-11981701-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240148723-A1 | MYCOBACTERIUM TUBERCULOSIS COMPOSITIONS AND METHODS | PZA INNOVATION LLC | 2024-05-09 | — | — | US | disclosed |
| EP-3795571-B1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024091894-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-3475275-B1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240092915-A1 | METHOD OF MODULATING CELL PROLIFERATION | Metro North Hospital and Health Service (AU) | 2024-03-21 | — | — | US | disclosed |
| US-11932854-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3833667-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11879012-B2 | Method of modulating cell proliferation | GILLIES, Peter (AU) | 2024-01-23 | — | — | US | disclosed |
| US-11840535-B2 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230348904-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | BANK OF AMERICA, N.A. | 2023-11-02 | — | — | US | disclosed |
| EP-3240572-B1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11746110-B2 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-09-05 | — | — | US | disclosed |
| EP-3808746-B1 | N-[3-[2-[8-[(1H-PYRAZOL-4-YL)AMINO]IMIDAZO[1,2-A]PYRAZIN-3-YL]ETHYNYL]PHENYL]-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SHENZHEN TARGETRX INC (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-20230219962-A1 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | MERCK SHARP & DOHME LLC (US) | 2023-07-13 | — | — | US | disclosed |
| CN-116392497-A | Anticancer medical application of glufosfamide | 深圳艾欣达伟医药科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023121939-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230192876-A1 | DOSING REGIMEN OF ANTI-CD27 ANTIBODIES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023071973-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | SHENZHEN TARGETRX, INC. (CN) | 2023-05-04 | — | — | WO | disclosed |
| US-20230114091-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4161522-A1 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | Merck Sharp & Dohme LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20230108114-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230108452-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP | 2023-04-06 | — | — | US | disclosed |
| US-20230104690-A1 | MATRIX METALLOPROTEINASE INHIBITORS (MMPIs) | BRANDON UNIV (CA) | 2023-04-06 | — | — | US | disclosed |
| US-20230092404-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP | 2023-03-23 | — | — | US | disclosed |
| US-20230083689-A1 | METHODS FOR TREATING CANCER WITH A WEE1 INHIBITOR | MERCK SHARP & DOHME LLC | 2023-03-16 | — | — | US | disclosed |
| EP-3706742-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| CN-110248664-B | Anticancer medical application of glufosfamide | 深圳艾欣达伟医药科技有限公司 | 2023-03-03 | — | — | CN | disclosed |
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM | 2023-02-09 | — | — | US | disclosed |
| US-20230030119-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS, INC | 2023-02-02 | — | — | US | disclosed |
| US-20230027885-A1 | TARGETING GENE AMPLIFICATION IN CANCER USING TRIPLEX FORMATION AS A THERAPEUTIC STRATEGY | YALE UNIVERSITY (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230027257-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | KANION USA INC. | 2023-01-26 | — | — | US | disclosed |
| US-11530407-B2 | Short interfering nucleic acid (siNA) compositions | SIRNA THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | disclosed |
| US-20220363707-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-4077282-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-4076452-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-4076460-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-4076459-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-4079856-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | Sirna Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022198325-A1 | CAMPTOTHECIN (CPT) DERIVATIVE(S) AND METHODS AND USES THEREOF | TRANMER GEOFFREY K G (CA) | 2022-09-29 | — | — | WO | disclosed |
| US-20220305048-A1 | USE OF HEPARIN TO PROMOTE TYPE 1 INTERFERON SIGNALING | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| EP-4051712-A1 | DOSING REGIMEN OF ANTI-CD27 ANTIBODIES FOR TREATMENT OF CANCER | Merck Sharp & Dohme LLC (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220251194-A1 | ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BICPECIFIC ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2022-08-11 | — | — | US | disclosed |
| US-11401340-B2 | Targeting gene amplification in cancer using triplex formation as a therapeutic strategy | YALE UNIVERSITY (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220195433-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA) | BANK OF AMERICA, N.A. | 2022-06-23 | — | — | US | disclosed |
| US-11364243-B2 | Methods for treating cancer with a WEE1 inhibitor | MERCK SHARP & DOHME CORP. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20220175777-A1 | Inhibitors of Multidrug Resistance Transporter P-Glycoprotein | SOUTHERN METHODIST UNIVERSITY | 2022-06-09 | — | — | US | disclosed |
| EP-4003523-A1 | ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | Merck Sharp & Dohme Corp. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11337978-B2 | Stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid | MERCK PATENT GMBH (DE) | 2022-05-24 | — | — | US | disclosed |
| US-20220143027-A1 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20220135671-A1 | ANTI-SIRP ALPHA ANTIBODIES | ADURO BIOTECH HOLDINGS, EUROPE B.V. (NL) | 2022-05-05 | — | — | US | disclosed |
| US-20220135677-A1 | ANTI-SIRP ALPHA ANTIBODIES | SAIROPA B.V. (NL) | 2022-05-05 | — | — | US | disclosed |
| EP-3240536-B1 | IMIDAZOPYRAZINE ANALOGS WITH 3-TERTIARY CARBON SUBSTITUTIONS AS BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2022-04-20 | — | — | EP | disclosed |
| US-11306094-B2 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20220110954-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2022-04-14 | — | — | US | disclosed |
| EP-3587574-B1 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3525886-B1 | COMPOSITIONS COMPRISING A METAL SOURCE, DITHIOCARBAMATE AND CYCLODEXTRIN | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS / UNIV HEIDELBERG (DE) | 2022-02-23 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2022-02-15 | — | — | US | disclosed |
| US-11234978-B2 | Inhibitors of multidrug resistance transporter P-glycoprotein | SOUTHERN METHODIST UNIVERSITY (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2022000071-A1 | MATRIX METALLOPROTEINASE INHIBITORS (MMPIS) | BRANDON UNIVERSITY (CA) | 2022-01-06 | — | — | WO | disclosed |
| EP-3925962-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE | Rakovina Therapeutics Inc. (CA) | 2021-12-22 | — | — | EP | disclosed |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-12-16 | — | — | US | disclosed |
| WO-2021252316-A1 | GRANULAR COMPOSITION OF AN ERK INHIBITOR AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3921647-A1 | IMPROVED DITHIOCARMABATE BASED COMPOUNDS, THERAPIES AND DIAGNOSTICS | Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg (DE) | 2021-12-15 | — | — | EP | disclosed |
| EP-3919620-A1 | SHORT INTERFERING NUCLEIC ACID (SINA) COMPOSITIONS | Sirna Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11193126-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210371530-A1 | ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | MERCK SHARP & DOHME LLC | 2021-12-02 | — | — | US | disclosed |
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | SHENZHEN TARGETRX, INC. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-20210363256-A1 | ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | MERCK SHARP & DOHME LLC | 2021-11-25 | — | — | US | disclosed |
| EP-3083560-B1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210309687-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309688-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3668516-B1 | STABLE LYOPHILISATES COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID AND A DICARBOXYLIC ACID | MERCK PATENT GMBH (DE) | 2021-09-22 | — | — | EP | disclosed |
| US-20210284646-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-09-16 | — | — | US | disclosed |
| US-20210277009-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-09-09 | — | — | US | disclosed |
| CN-113214246-A | Protein kinase C inhibitors and methods of their use | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-11072658-B2 | Anti-PD-1/LAG3 bispecific antibodies | MERCK SHARP & DOHME CORP. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210222175-A1 | TARGETING GENE AMPLIFICATION IN CANCER USING TRIPLEX FORMATION AS A THERAPEUTIC STRATEGY | YALE UNIVERSITY (US) | 2021-07-22 | — | — | US | disclosed |
| US-11066396-B2 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2021-07-13 | — | — | US | disclosed |
| US-20210206874-A9 | TARGETING GENE AMPLIFICATION IN CANCER USING TRIPLEX FORMATION AS A THERAPEUTIC STRATEGY | YALE UNIVERSITY (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210205389-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | CHANG GUNG MEDICAL FOUND KEELUNG CHANG GUNG MEMORIAL HOSPITAL (TW) | 2021-07-08 | — | — | US | disclosed |
| WO-2021126731-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126729-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126732-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126728-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3277313-B1 | AGENTS AND COMPOSITIONS FOR ELICITING AN IMMUNE RESPONSE | CANCURE LTD (AU) | 2021-06-23 | — | — | EP | disclosed |
| EP-3833667-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3833668-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3833355-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3833669-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-11013739-B2 | Inhibitors of multidrug resistance transporter p-glycoprotein | SOUTHERN METHODIST UNIVERSITY (US) | 2021-05-25 | — | — | US | disclosed |
| CN-106795151-B | Protein kinase C inhibitors and methods of their use | 诺华股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| WO-2021087016-A1 | DOSING REGIMEN OF ANTI-CD27 ANTIBODIES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-2623101-B1 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2021-04-21 | — | — | EP | disclosed |
| EP-3453762-B1 | SHORT INTERFERING NUCLEIC ACID (SINA) COMPOSITIONS | SIRNA THERAPEUTICS INC (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3808746-A1 | ALKYNYL (HETERO) AROMATIC RING COMPOUNDS USED FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-10975084-B2 | KDM5 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3795571-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2021-03-24 | — | — | EP | disclosed |
| US-10953059-B2 | Methods and compositions for treating non-small cell lung cancer | CHANG GUNG MEDICAL FOUNDATION KEELUNG CHANG GUNG MEMORIAL HOSPITAL (TW) | 2021-03-23 | — | — | US | disclosed |
| US-10953045-B2 | Agents and compositions for eliciting an immune response | CANCURE LIMITED (AU) | 2021-03-23 | — | — | US | disclosed |
| US-10953099-B2 | Compositions comprising a metal source, dithiocarbamate and cyclodextrin | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2021-03-23 | — | — | US | disclosed |
| US-10947234-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen TargetRx. Inc. (CN) | 2021-03-11 | — | — | US | disclosed |
| EP-3083559-B1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-2714703-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2021-03-10 | — | — | EP | disclosed |
| WO-2021041532-A1 | USE OF HEPARIN TO PROMOTE TYPE 1 INTERFERON SIGNALING | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-10933049-B2 | Mobilizing agents and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-03-02 | — | — | US | disclosed |
| WO-2021021767-A1 | ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20210032342-A1 | ANTI-PD-1 ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2021-02-04 | — | — | US | disclosed |
| US-10898485-B2 | Inhibitors of multidrug resistance transporter p-glycoprotein | SOUTHERN METHODIST UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3766975-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | Sirna Therapeutics, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3082809-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3758715-A1 | A METHOD OF MODULATING CELL PROLIFERATION | Gillies, Peter (AU) | 2021-01-06 | — | — | EP | disclosed |
| US-20200407451-A1 | A METHOD OF MODULATING CELL PROLIFERATION | Metro North Hospital and Health Service (AU) | 2020-12-31 | — | — | US | disclosed |
| US-20200392499-A1 | SHORT INTERFERING NUCLEIC ACID (SINA) COMPOSITIONS | BANK OF AMERICA, N.A. | 2020-12-17 | — | — | US | disclosed |
| EP-3746120-A1 | ANTI-PD-1 ANTIBODIES | Merck Sharp&Dohme Corp. (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3746481-A1 | ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3492471-B1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | SHENZHEN TARGETRX INC (CN) | 2020-12-02 | — | — | EP | disclosed |
| US-10851164-B2 | Anti-SIRPα antibodies | ADURO BIOTECH HOLDINGS, EUROPE B.V. (NL) | 2020-12-01 | — | — | US | disclosed |
| US-20200368236-A1 | Stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid | MERCK PATENT GMBH (DE) | 2020-11-26 | — | — | US | disclosed |
| US-20200361931-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200354377-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10815291-B2 | Polynucleotides encoding immune modulating polypeptides | MODERNATX, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| EP-3240546-B1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-10-21 | — | — | EP | disclosed |
| US-10793860-B2 | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (SINA) | SIRNA THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | RAKOVINA THERAPEUTICS INC. (CA) | 2020-09-24 | — | — | US | disclosed |
| EP-3706747-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3706742-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200283443-A1 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2020-09-10 | — | — | US | disclosed |
| US-10759805-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200262814-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2020-08-20 | — | — | US | disclosed |
| EP-2488028-B1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2020161337-A1 | IMPROVED DITHIOCARMABATE BASED COMPOUNDS, THERAPIES AND DIAGNOSTICS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2020-08-13 | — | — | WO | disclosed |
| EP-3693740-A1 | IMPROVED DITHIOCARMABATE BASED COMPOUNDS, THERAPIES AND DIAGNOSTICS | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts (DE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3327125-B1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA) | SIRNA THERAPEUTICS INC (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200239937-A1 | BIOMARKERS FOR DIAGNOSING CONDITIONS | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2020-07-30 | — | — | US | disclosed |
| US-20200199596-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2020-06-25 | — | — | US | disclosed |
| EP-3668516-A1 | STABLE LYOPHILISATES COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID AND A DICARBOXYLIC ACID | Merck Patent GmbH (DE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3358013-B1 | SHORT INTERFERING NUCLEIC ACID (SINA) COMPOSITIONS | SIRNA THERAPEUTICS INC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10689648-B2 | Short interfering nucleic acid (siNA) compositions | SIRNA THERAPEUTICS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200190211-A1 | TARGETING GENE AMPLIFICATION IN CANCER USING TRIPLEX FORMATION AS A THERAPEUTIC STRATEGY | YALE UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
| EP-2971010-B1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200171035-A1 | METHODS FOR TREATING CANCER WITH A WEE1 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200138816-A1 | Inhibitors of Multidrug Resistance Transporter P-Glycoprotein | SOUTHERN METHODIST UNIVERSITY | 2020-05-07 | — | — | US | disclosed |
| EP-3280418-B1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200131272-A1 | ANTI-CD27 ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2020-04-30 | — | — | US | disclosed |
| CN-110896604-A | Anticancer medical application of Evoxamine | 深圳艾欣达伟医药科技有限公司 | 2020-03-20 | — | — | CN | disclosed |
| US-20200069687-A1 | Inhibitors of Multidrug Resistance Transporter P-Glycoprotein | SOUTHERN METHODIST UNIVERSITY | 2020-03-05 | — | — | US | disclosed |
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-10570134-B2 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2020-02-25 | — | — | US | disclosed |
| EP-3609922-A2 | ANTI-SIRP ALPHA ANTIBODIES | Aduro Biotech Holdings, Europe B.V. (NL) | 2020-02-19 | — | — | EP | disclosed |
| WO-2020033288-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-20200048258-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048259-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | US | disclosed |
| WO-2020033284-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033285-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033282-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-10556957-B2 | Anti-CD27 antibodies | MERCK SHARP & DOHME CORP. (US) | 2020-02-11 | — | — | US | disclosed |
| CN-104945382-B | Substituted piperidines that increase p53 activity and uses thereof | 默沙东公司 | 2020-02-07 | — | — | CN | disclosed |
| US-10548893-B2 | Inhibitors of multidrug resistance transporter P-glycoprotein | SOUTHERN METHODIST UNIVERSITY (US) | 2020-02-04 | — | — | US | disclosed |
| US-10543210-B2 | Inhibitors of multidrug resistance transporter P-glycoprotein | SOUTHERN METHODIST UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
| CN-110680824-A | Anticancer medical application of Evoxamine | 深圳艾欣达伟医药科技有限公司 | 2020-01-14 | — | — | CN | disclosed |
| WO-2020007106-A1 | MEDICAL USE OF EVOFOSFAMIDE IN ANTI-CANCER | 深圳艾欣达伟医药科技有限公司 | 2020-01-09 | — | — | WO | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190328886-A1 | COMPOSITIONS COMPRISING A METAL SOURCE, DITHIOCARBAMATE AND CYCLODEXTRIN | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2019-10-31 | — | — | US | disclosed |
| US-20190330639-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | MERCK SHARP & DOHME CORP. | 2019-10-31 | — | — | US | disclosed |
| EP-3280419-B1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190300618-A1 | ANTI-CD27 ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2019-10-03 | — | — | US | disclosed |
| CN-110269862-A | The anticancer medical usage of glufosfamide | 深圳艾欣达伟医药科技有限公司 | 2019-09-24 | — | — | CN | disclosed |
| EP-3177608-B1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| CN-110248664-A | The anticancer medical usage of glufosfamide | 深圳艾欣达伟医药科技有限公司 | 2019-09-17 | — | — | CN | disclosed |
| EP-3536319-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3536690-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | MSD Italia S.r.l. (IT) | 2019-09-11 | — | — | EP | disclosed |
| US-10407682-B2 | RNA interference mediated inhibition of hepatitis B Virus (HBV) gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190270745-A1 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2019-09-05 | — | — | US | disclosed |
| EP-3525786-A1 | KDM5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3525785-A1 | KDM5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3525886-A1 | COMPOSITIONS COMPRISING A METAL SOURCE, DITHIOCARBAMATE AND CYCLODEXTRIN | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-2988749-B1 | THIAZOLE-SUBSTITUTED AMINOPYRIMIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-08-14 | — | — | EP | disclosed |
| WO-2019152642-A1 | ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152571-A1 | ANTI-PD-1 ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019148410-A1 | ANTI-PD-1 ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019148412-A1 | ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2019-08-08 | — | — | WO | disclosed |
| EP-3233859-B1 | BRIDGED PYRAZOLOPYRIDINE DERIVATIVES AS ERK INHIBITORS USEFUL FOR THE TREATEMENT OF CANCER | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190233518-A1 | ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | ZYMEWORKS BC INC. (CA) | 2019-08-01 | — | — | US | disclosed |
| EP-3515941-A1 | ANTI-CD27 ANTIBODIES | Merck Sharp & Dohme Corp. (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3514151-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2019-07-24 | — | — | EP | disclosed |
| US-20190216811-A1 | Inhibitors of Multidrug Resistance Transporter P-Glycoprotein | SOUTHERN METHODIST UNIVERSITY | 2019-07-18 | — | — | US | disclosed |
| US-20190202809-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-07-04 | — | — | US | disclosed |
| US-10336758-B2 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2019-07-02 | — | — | US | disclosed |
| US-20190185462-A1 | 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
| CN-109890846-A | anti-CD 27 antibodies | 默沙东公司 | 2019-06-14 | — | — | CN | disclosed |
| EP-2470499-B1 | NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF | ALBERTA HEALTH SERVICES (CA) | 2019-06-12 | — | — | EP | disclosed |
| EP-3492471-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
| CN-109833324-A | The anticancer medical usage of glufosfamide | 深圳艾欣达伟医药科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-10292982-B2 | Inhibitors of multidrug resistance transporter P-glycoprotein | SOUTHERN METHODIST UNIVERSITY (US) | 2019-05-21 | — | — | US | disclosed |
| US-20190142971-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
| EP-2934525-B1 | THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2948458-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3475275-A1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3116506-B1 | 2-PYRAZINE CARBOXAMIDES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10258698-B2 | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions | MODERNATX, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| EP-2606134-B1 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS INC (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | disclosed |
| US-10246457-B2 | Indazole and azaindazole Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246714-B2 | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190091223-A1 | Inhibitors of Multidrug Resistance Transporter P-Glycoprotein | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
| EP-3453762-A1 | SHORT INTERFERING NUCLEIC ACID (SINA) COMPOSITIONS | Sirna Therapeutics, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2948431-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2019034673-A1 | STABLE LYOPHILISATES COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID AND A DICARBOXYLIC ACID | MERCK PATENT GMBH (DE) | 2019-02-21 | — | — | WO | disclosed |
| CN-105307656-B | Quinoline inhibitors of macrophage stimulating 1 receptor MST1R | 利德发现中心有限责任公司 | 2019-02-19 | — | — | CN | disclosed |
| US-10208047-B2 | Tertiary alcohol imidazopyrazine BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2736338-B1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20190016781-A1 | POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2019-01-17 | — | — | US | disclosed |
| US-10172855-B2 | Inhibitors of multidrug resistance transporter P-glycoprotein | SOUTHERN METHODIST UNIVERSITY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180362977-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) | BANK OF AMERICA, N.A. | 2018-12-20 | — | — | US | disclosed |
| US-20180360879-A1 | AGENTS AND COMPOSITIONS FOR ELICITING AN IMMUNE RESPONSE | CANCURE LIMITED (AU) | 2018-12-20 | — | — | US | disclosed |
| EP-2935263-B1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-2991654-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-11-21 | — | — | EP | disclosed |
| US-10130630-B2 | BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180319804-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-11-08 | — | — | US | disclosed |
| US-20180312587-A1 | ANTI-SIRP ALPHA ANTIBODIES | ADURO BIOTECH HOLDINGS, EUROPE B.V. (NL) | 2018-11-01 | — | — | US | disclosed |
| EP-2029551-B1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MSD ITALIA SRL (IT) | 2018-10-31 | — | — | EP | disclosed |
| US-20180303807-A1 | ANDROGEN RECEPTOR LIGANDS | UNITED STATES GOVERNMENT | 2018-10-25 | — | — | US | disclosed |
| EP-2584903-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-10-24 | — | — | EP | disclosed |
| CN-108676800-A | The inhibition led using the mediated rnai of hepatitis type B virus (HBV) gene expression of short interfering nucleic acid (siNA) | 瑟纳治疗公司 | 2018-10-19 | — | — | CN | disclosed |
| EP-2844261-B1 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | SIRNA THERAPEUTICS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10093623-B2 | Cyclic amides as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| EP-2863914-B1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-10-03 | — | — | EP | disclosed |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| WO-2018170553-A1 | COMPLEXES AND USES THEREOF | CURTIN UNIVERSITY OF TECHNOLOGY (AU) | 2018-09-27 | — | — | WO | disclosed |
| EP-3082810-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-2915539-B1 | Treatment of immunocompromised conditions with an E-Selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells | MATER MEDICAL RES INSTITUTE (AU) | 2018-09-19 | — | — | EP | disclosed |
| EP-3086802-B1 | CD44 BINDING PEPTIDES | EXCHANGE IMAGING TECH GMBH (DE) | 2018-09-19 | — | — | EP | disclosed |
| EP-2863913-B1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2734529-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-10065967-B2 | Compounds that are ERK inhibitors | Merck, Sharp & Dohme Corp. (US) | 2018-09-04 | — | — | US | disclosed |
| WO-2018152585-A1 | \"BIOMARKERS FOR DIAGNOSING CONDITIONS\ | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2018-08-30 | — | — | WO | disclosed |
| US-10059710-B2 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2018-08-28 | — | — | US | disclosed |
| EP-2706852-B1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2714677-B1 | PYRIDINE-AND PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | disclosed |
| EP-2900241-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3358013-A1 | SHORT INTERFERING NUCLEIC ACID (SINA) COMPOSITIONS | Sirna Therapeutics, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10040805-B2 | Substituted imidazo[1,5-a]pyrazines as Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180214579-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| EP-2863916-B1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2018-07-18 | — | — | EP | disclosed |
| CN-108289922-A | Therapeutic methods and compositions for treating non-small cell lung cancer | 友杏生技医药股份有限公司 | 2018-07-17 | — | — | CN | disclosed |
| US-10023626-B2 | Polynucleotides encoding immune modulating polypeptides | MODERNATX, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180195071-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2018-07-12 | — | — | US | disclosed |
| CN-103282497-B | RNA interference-mediated suppression of Hepatitis B Virus (HBV) gene expression using short interfering nucleic acids (siNA) | 瑟纳治疗公司 | 2018-07-10 | — | — | CN | disclosed |
| US-20180185328-A1 | MOBILIZING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-07-05 | — | — | US | disclosed |
| US-20180185366-A1 | Inhibitors of Multidrug Resistance Transporter P-Glycoprotein | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-05 | — | — | US | disclosed |
| EP-3082807-B1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180179181-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-28 | — | — | US | disclosed |
| EP-3330377-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | Sirna Therapeutics, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9988397-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-3327125-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA) | Sirna Therapeutics, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180134711-A1 | New stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2018-05-17 | — | — | US | disclosed |
| US-9970005-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20180127411-A1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180118766-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-2951180-B1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| CN-105050598-B | Novel compounds as ERK inhibitors | 默沙东公司 | 2018-04-27 | — | — | CN | disclosed |
| CN-102958930-B | [1,8] naphthyridine compounds as the 2,4- diaryl substitution for the kinase inhibitor to anticancer | 默克专利有限公司 | 2018-04-27 | — | — | CN | disclosed |
| EP-3311843-A1 | COMPOSITIONS COMPRISING DITHIOCARBAMATE AND CYCLODEXTRIN | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts (DE) | 2018-04-25 | — | — | EP | disclosed |
| EP-3310174-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | OP NANO CO., LTD. (TW) | 2018-04-25 | — | — | EP | disclosed |
| WO-2018069525-A1 | COMPOSITIONS COMPRISING A METAL SOURCE, DITHIOCARBAMATE AND CYCLODEXTRIN | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018071283-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018071282-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20180105812-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | BANK OF AMERICA, N.A. | 2018-04-19 | — | — | US | disclosed |
| EP-3302480-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3302710-A1 | MOBILIZING AGENTS AND USES THEREFOR | The University of Queensland (AU) | 2018-04-11 | — | — | EP | disclosed |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | disclosed |
| EP-2770987-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20180086841-A1 | ANTI-CD27 ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2018-03-29 | — | — | US | disclosed |
| WO-2018058022-A1 | ANTI-CD27 ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-9925277-B2 | Polynucleotide compositions containing amino acids | MODERNATX, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180079752-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| CN-107708725-A | Agents and compositions for eliciting an immune response | 坎库雷有限公司 | 2018-02-16 | — | — | CN | disclosed |
| EP-3280419-A1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| EP-3280418-A1 | AZACARBAZOLE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| EP-3277313-A1 | AGENTS AND COMPOSITIONS FOR ELICITING AN IMMUNE RESPONSE | Cancure Limited (AU) | 2018-02-07 | — | — | EP | disclosed |
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20180030454-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2018-02-01 | — | — | US | disclosed |
| EP-3103791-B1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9879262-B2 | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| EP-3003315-B1 | A QUINOLINE INHIBITOR OF THE MACROPHAGE STIMULATING 1 RECEPTOR MST1R | LEAD DISCOVERY CENTER GMBH (DE) | 2018-01-17 | — | — | EP | disclosed |
| US-9868705-B2 | Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180009828-A1 | IMIDAZOPYRAZINE ANALOGS WITH 3-TERTIARY CARBON SUBSTITUTIONS AS BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-2900665-B1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2017222950-A1 | 3-HETEROCYCLYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017222952-A1 | 3- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017222951-A1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-9850491-B2 | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362243-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9845309-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-20170349593-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-07 | — | — | US | disclosed |
| EP-2601293-B1 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS INC (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2863915-B1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9834554-B2 | BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| CN-105712991-B | 7 7-azaindole derivatives | 默克专利股份公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-105732617-B | 7 7-azaindole derivatives | 默克专利股份公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340631-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
| US-9822107-B2 | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170320882-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| EP-3240546-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240542-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240572-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240536-A1 | IMIDAZOPYRAZINE ANALOGS WITH 3-TERTIARY CARBON SUBSTITUTIONS AS BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240543-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240545-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240544-A2 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2017190059-A1 | STABILIZING PROINSULIN MONOMERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-02 | — | — | WO | disclosed |
| EP-2925888-B1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3233858-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2900223-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3233859-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-25 | — | — | EP | disclosed |
| CN-104245675-B | Cyclic amides as MetAP-2 inhibitors | 默克专利股份公司 | 2017-10-13 | — | — | CN | disclosed |
| US-9783531-B2 | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2010528-B1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-9775839-B2 | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267695-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2884982-B1 | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9745295-B2 | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745307-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| CN-107090456-A | The connection albumen led using the mediated rnai of short interfering nucleic acid（Cadherin related protein matter）, the suppression of the gene expressions of β 1 | 瑟纳治疗公司 | 2017-08-25 | — | — | CN | disclosed |
| US-20170233394-A1 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2017-08-17 | — | — | US | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2934535-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170173128-A1 | TARGETED ADAPTIVE VACCINES | MODERNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-2621925-B1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9682978-B2 | 2,6,7 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2706853-B1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-3177608-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2017-06-14 | — | — | EP | disclosed |
| EP-2714668-B9 | THIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-06-14 | — | — | EP | disclosed |
| EP-2886126-B1 | Nanoparticle conjugated to CD44 binding peptides | EXCHANGE IMAGING TECH GMBH (DE) | 2017-06-07 | — | — | EP | disclosed |
| US-9670196-B2 | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-06-06 | — | — | US | disclosed |
| CN-106795151-A | Protein kinase C inhibitors and methods of their use | 诺华股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9655899-B2 | Compositions and methods for treating cancer | MERCK SHARP & DOHME CORP. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170128447-A1 | Inhibitors of Multidrug Resistance Transporter P-Glycoprotein | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-05-11 | — | — | US | disclosed |
| US-9637486-B2 | Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637493-B2 | Substituted pyrrolopyrimidines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170095479-A1 | Methods for Treating Cancer with a WEE1 Inhibitor | MERCK SHARP & DOHME CORP. (US) | 2017-04-06 | — | — | US | disclosed |
| EP-3148544-A1 | METHODS FOR TREATING CANCER WITH A WEE1 INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2017-04-05 | — | — | EP | disclosed |
| CN-103068980-B | RNA interference mediated inhibition of the catenin (cadherin-associated protein), beta 1 (CTNNB 1) gene expression using short interfering nucleic acids (siNA) | 瑟纳治疗公司 | 2017-04-05 | — | — | CN | disclosed |
| CN-103930416-B | BENZONITRILE DERIVATIVES AS KINASE INHIBITORS | 默克专利股份公司 | 2017-03-29 | — | — | CN | disclosed |
| CN-105073746-B | Substituted imidazopyridines as HDM2 inhibitors | 默沙东公司 | 2017-03-22 | — | — | CN | disclosed |
| US-9598405-B2 | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170071935-A1 | 2-PYRAZINE CARBOXAMIDES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073392-A1 | CD44 BINDING PEPTIDES | EXCHANGE IMAGING TECHNOLOGIES GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-9586931-B2 | Triazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170057984-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2017-03-02 | — | — | US | disclosed |
| US-9561227-B2 | Inhibitors of multidrug resistance transporter P-glycoprotein | SOUTHERN METHODIST UNIVERSITY (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170029824-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2017-02-02 | — | — | US | disclosed |
| EP-3116506-A1 | 2-PYRAZINE CARBOXAMIDES AS SPLEEN TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2707357-B1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2714668-B1 | THIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-01-18 | — | — | EP | disclosed |
| CN-103946223-B | 3-cyanaryl-1h-pyrazolo[2.3-b]pyridine derivatives | 默克专利股份公司 | 2017-01-18 | — | — | CN | disclosed |
| US-9546168-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9540377-B2 | 2,6,7,8 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2615916-B1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-01-04 | — | — | EP | disclosed |
| CN-103596938-B | Thiazole | 默克专利有限公司 | 2016-12-28 | — | — | CN | disclosed |
| US-20160369279-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2016-12-22 | — | — | US | disclosed |
| EP-3103791-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2016197012-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | ORIENT PHARMA INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016192074-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016191811-A1 | MOBILIZING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196418-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | TEXAS TECH UNIVERSITY SYSTEM | 2016-12-01 | — | — | US | disclosed |
| US-9505784-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160340351-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2016-11-24 | — | — | US | disclosed |
| US-9499534-B2 | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160326164-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326156-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | US | disclosed |
| EP-2513098-B1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-9487504-B2 | Imidazolyl analogs as syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9481682-B2 | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481668-B2 | Quinoline inhibitor of the macrophage stimulating 1 receptor MSTR1 | MERCK PATENT GMBH (DE) | 2016-11-01 | — | — | US | disclosed |
| US-20160311819-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311813-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311820-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3082807-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-3082810-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2742043-B1 | PYRIDO-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-3082811-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-3082809-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-3083560-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-3083559-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-1987024-B1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | MSD ITALIA SRL (IT) | 2016-10-19 | — | — | EP | disclosed |
| WO-2016161571-A1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016161570-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164284-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164285-A1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| EP-3076994-A2 | TARGETED ADAPTIVE VACCINES | Moderna Therapeutics, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| CN-106008460-A | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide | 默沙东有限公司 | 2016-10-12 | — | — | CN | disclosed |
| US-9464290-B2 | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| WO-2016154684-A1 | AGENTS AND COMPOSITIONS FOR ELICITING AN IMMUNE RESPONSE | CANCURE LIMITED (AU) | 2016-10-06 | — | — | WO | disclosed |
| US-9458101-B2 | Colchicine derivatives, methods and uses thereof | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2016-10-04 | — | — | US | disclosed |
| US-9452998-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-9452997-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| US-9446130-B2 | BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447420-B2 | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (SINA) | SIRNA THERAPEUTICS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160264964-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160257962-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF ISOCITRATE DEHYDROGENASE (IDH1) GENE EXPRESSION | SIRNA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| EP-2793890-B1 | SUBSTITUTED PIPERIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2812337-B1 | FURO [3, 2 - B]PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-20160244502-A1 | POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-25 | — | — | US | disclosed |
| US-20160243259-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-25 | — | — | US | disclosed |
| US-20160237064-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9416111-B2 | Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20160229811-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | DUKE UNIVERSITY | 2016-08-11 | — | — | US | disclosed |
| EP-3052106-A2 | POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES | Moderna Therapeutics, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| US-9408816-B2 | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy | PHARMACYCLICS LLC (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2023924-B1 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2654748-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-3043826-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | Moderna Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3041934-A1 | CHIMERIC POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-3041938-A1 | CIRCULAR POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016109223-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109217-A2 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160194625-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX, INC. | 2016-07-07 | — | — | US | disclosed |
| WO-2016109219-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109221-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109222-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109215-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109216-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| WO-2016109220-A1 | IMIDAZOPYRAZINE ANALOGS WITH 3-TERTIARY CARBON SUBSTITUTIONS AS BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160194368-A1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| WO-2016106629-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016106652-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016106624-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016106627-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016106623-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016106628-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016106626-A1 | IMIDAZOPYRAZINE ANALOGS WITH 3-TERTIARY CARBON SUBSTITUTIONS AS BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| CN-105732617-A | 7-azaindole derivatives | 默克专利股份公司 | 2016-07-06 | — | — | CN | disclosed |
| US-9382244-B2 | 7-azaindole-2,7-naphthyridine derivative for the treatment of tumours | MERCK PATENT GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| CN-105712991-A | 7-AZAINDOLE DERIVATIVES | 默克专利股份公司 | 2016-06-29 | — | — | CN | disclosed |
| US-9376418-B2 | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| WO-2016100050-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100051-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016095088-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| CN-103717600-B | Pyridopyrimidine derivatives | 默克专利股份公司 | 2016-06-22 | — | — | CN | disclosed |
| EP-2608669-B1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2016-06-22 | — | — | EP | disclosed |
| US-9371281-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYCLICS LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160166608-A1 | METHODS OF TREATING CANCER WITH HIGH POTENCY LIPID-BASED PLATINUM COMPOUND FORMULATIONS ADMINISTERED INTRAPERITONEALLY | INSMED INC (US) | 2016-06-16 | — | — | US | disclosed |
| EP-2608668-B1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MERCK SHARP & DOHME (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2755482-B1 | COMBINATION OF MK-1775 AND MK-8776 FOR TREATING CANCER | MERCK SHARP & DOHME (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9351965-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353066-B2 | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160143927-A1 | Compounds, Methods, and Treatments for Abnormal Signaling Pathways for Prenatal and Postnatal Development | JENNINGS BARBARA BROOKE (US) | 2016-05-26 | — | — | US | disclosed |
| CN-103153951-B | Pyrrolidones as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | CN | disclosed |
| EP-2007733-B1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-25 | — | — | EP | disclosed |
| EP-3023426-A1 | THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS | Critical Outcome Technologies, Inc. (CA) | 2016-05-25 | — | — | EP | disclosed |
| CN-103748086-B | Pyridine and pyrazines derivatives | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | CN | disclosed |
| US-9345705-B2 | Compositions and methods for treating cancer | MERCK SHARP & DOHME CORP. (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2170076-B1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20160130269-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130659-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. (US) | 2016-05-12 | — | — | US | disclosed |
| CN-103717609-B | Tricyclic inhibitors of poly (ADP-ribose) polymerase | JIANGSU KANION PHARMACEUTICAL Co.,Ltd. (CN) | 2016-05-11 | — | — | CN | disclosed |
| EP-1926721-B1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-04 | — | — | EP | disclosed |
| US-20160115154-A1 | Quinoline Inhibitor of the Macrophage Stimulating 1 Receptor MSTR1 | MERCK PATENT GMBH (DE) | 2016-04-28 | — | — | US | disclosed |
| US-9322020-B2 | RNA interference mediated inhibition of isocitrate dehydrogenase (IDH1) gene expression | SIRNA THERAPEUTICS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| EP-3004395-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Merck Sharp & Dohme Corp. (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-3003315-A1 | A QUINOLINE INHIBITOR OF THE MACROPHAGE STIMULATING 1 RECEPTOR MST1 R | Merck Patent GmbH (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2265590-B1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-9308205-B2 | Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyrdazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof | MERCK PATENT GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| CN-103052633-B | The indazole derivatives that amide group replaces is birdsed of the same feather flock together (ADP-ribose) AG14361 | BETTA PHARMACEUTICALS Co.,Ltd. (CN) | 2016-03-23 | — | — | CN | disclosed |
| US-9289427-B2 | Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-hydrochloride salt and processes of manufacturing thereof | MERCK PATENT GMBH (DE) | 2016-03-22 | — | — | US | disclosed |
| US-9290490-B2 | Aminopyrimidines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160076034-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2016-03-17 | — | — | US | disclosed |
| CN-103205407-B | Soluble PH 20 polypeptides extended and uses thereof | HALOZYME, INC. (US) | 2016-03-16 | — | — | CN | disclosed |
| US-9283225-B2 | Pyrido-pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-9284275-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2016-03-15 | — | — | US | disclosed |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| EP-1885349-B1 | Sulphamides for treatment of cancer | MERCK SHARP & DOHME (GB) | 2016-03-09 | — | — | EP | disclosed |
| EP-2991654-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20160060256-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIMIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060255-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK CANADA INC. (CA) | 2016-03-03 | — | — | US | disclosed |
| EP-2988744-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2988749-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIMIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-03-02 | — | — | EP | disclosed |
| CN-105377251-A | Mobilizing agents and uses thereof | MATER MEDICAL RES INST LTD | 2016-03-02 | — | — | CN | disclosed |
| CN-103189378-B | As the Pyrazolopyridine ketone derivatives of LPA receptor antagonist | MERCK PATENT GMBH (DE) | 2016-03-02 | — | — | CN | disclosed |
| US-9273029-B2 | Pyridine-and pyrazine derivatives | MERCK PATENT GMBH (DE) | 2016-03-01 | — | — | US | disclosed |
| CN-103502247-B | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2016-02-24 | — | — | CN | disclosed |
| CN-103391938-B | Pyrido [2,3-B] pyrazines derivatives and therepic use thereof | MERCK PATENT GMBH (DE) | 2016-02-24 | — | — | CN | disclosed |
| US-9266887-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2016-02-23 | — | — | US | disclosed |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-18 | — | — | US | disclosed |
| EP-2220061-B1 | SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9260471-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260417-B2 | Therapeutic methods and compositions involving allosteric kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| WO-2016020864-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-11 | — | — | WO | disclosed |
| US-20160038612-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | ARES CAPITAL CORPORATION, AS AGENT | 2016-02-11 | — | — | US | disclosed |
| US-9254322-B2 | Compositions comprising E-selectin antagonists and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-02-09 | — | — | US | disclosed |
| CN-103403005-B | 5- ([1,2,3] -triazol-4-yl) -7H-pyrrolo [2,3-d ] pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-02-03 | — | — | CN | disclosed |
| CN-105307656-A | Quinoline inhibitors of macrophage stimulating 1 receptor MST1R | MERCK PATENT GMBH | 2016-02-03 | — | — | CN | disclosed |
| US-9249114-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| EP-2318406-B1 | THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS | CRITICAL OUTCOME TECHNOLOGIES INC (CA) | 2016-01-27 | — | — | EP | disclosed |
| US-9242984-B2 | Pyrazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2016-01-21 | — | — | US | disclosed |
| EP-2971010-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | Moderna Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9238651-B2 | 1-H-pyrrolo[2,3-b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2016-01-19 | — | — | US | disclosed |
| US-20160008361-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. (US) | 2016-01-14 | — | — | US | disclosed |
| CN-103694258-B | For suppressing 1,3,4-thiadiazoles derivative of the spiral shell condensation of KSP kinesin activity | SCHERING CORPORATION (US) | 2016-01-13 | — | — | CN | disclosed |
| US-9233979-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2961398-A1 | MOBILIZING AGENTS AND USES THEREFOR | Mater Medical Research Institute Limited (AU) | 2016-01-06 | — | — | EP | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9226922-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150368247-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-24 | — | — | US | disclosed |
| EP-2953470-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-16 | — | — | EP | disclosed |
| US-20150353535-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353570-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353565-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2951180-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2015183776-A1 | METHODS FOR TREATING CANCER WITH A WEE1 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2015-12-03 | — | — | WO | disclosed |
| EP-2948431-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2948458-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-02 | — | — | EP | disclosed |
| CN-102666538-B | Pyrrolopyridinylpyri-idin-idin 2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| EP-2946778-A1 | METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150329548-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-19 | — | — | US | disclosed |
| CN-105073746-A | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME | 2015-11-18 | — | — | CN | disclosed |
| US-9186347-B1 | Hydroxamates as therapeutic agents | PHARMACYCLICS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150320758-A1 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| CN-105050598-A | Novel compounds as ERK inhibitors | MERCK SHARP & DOHME | 2015-11-11 | — | — | CN | disclosed |
| EP-2934525-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2934535-A2 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2935263-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9169260-B2 | Amidopyrazole inhibitors of interleukin receptor-associated kinases | MERCK SHARP & DOHME CORP. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150299119-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299125-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299696-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | SIRNA THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| CN-103168042-B | 7-([1,2,3]-triazole-4-yl) pyrrolo-[2,3-b] pyrazines derivatives | MERCK PATENT GMBH (DE) | 2015-10-21 | — | — | CN | disclosed |
| CN-102391222-B | As the hydroxamic acid ester of therapeutical agent | PHARMACYCLICS INC. (US) | 2015-10-21 | — | — | CN | disclosed |
| EP-2925888-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Merck Sharp & Dohme Corp. (US) | 2015-10-07 | — | — | EP | disclosed |
| CN-103180320-B | 1H-pyrrolo [2,3-b ] pyridine derivatives | MERCK PATENT GMBH (DE) | 2015-10-07 | — | — | CN | disclosed |
| CN-104945382-A | Substituted piperidines that increase p53 activity and uses thereof | SCHERING CORP | 2015-09-30 | — | — | CN | disclosed |
| US-9145391-B2 | Bipyridylaminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2015138273-A1 | 2-PYRAZINE CARBOXAMIDES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | WO | disclosed |
| EP-2916837-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2013196-B1 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-09-16 | — | — | EP | disclosed |
| CN-102480966-B | Fused heterocyclic compounds and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-09-16 | — | — | CN | disclosed |
| US-20150252041-A1 | 7-AZAINDOLE-2,7-NAPHTHYRIDINE DERIVATIVE FOR THE TREATMENT OF TUMOURS | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
| EP-2915539-A1 | Treatment of immunocompromised conditions with E-Selectin antagonist and G-CSF | Mater Medical Research Institute (AU) | 2015-09-09 | — | — | EP | disclosed |
| CN-102822171-B | As the benzo naphthyridines amine of autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2015-09-02 | — | — | CN | disclosed |
| US-9120785-B2 | Pyridyl aminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-27 | — | — | US | disclosed |
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-20 | — | — | US | disclosed |
| CN-102858767-B | As the aminopyrimidine of SYK inhibitor | MERCK SHARP & DOHME CORP. (US) | 2015-08-19 | — | — | CN | disclosed |
| CN-103764651-B | Be applicable to the 7-7-azaindole derivatives of Therapeutic cancer disease | MERCK PATENT GMBH (DE) | 2015-08-19 | — | — | CN | disclosed |
| US-9107824-B2 | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally | INSMED INCORPORATED (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2015120254-A1 | DISULFIRAM COMPOSITIONS AND TREATMENTS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2015-08-13 | — | — | WO | disclosed |
| EP-2406250-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2015-08-12 | — | — | EP | disclosed |
| US-9102675-B2 | 3-Cyanoaryl-1H-pyrrolo[2,3-B] pyridine derivatives | MERCK PATENT GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| EP-2900665-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2900223-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2900241-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| US-9096559-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2240466-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME (GB) | 2015-07-29 | — | — | EP | disclosed |
| EP-1976833-B1 | HETEROCYCLE SUBSTITUTED AMIDE AND SULFUR AMIDE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | MSD ITALIA SRL (IT) | 2015-07-29 | — | — | EP | disclosed |
| CN-102638981-B | Substituted piperidines that increase p53 activity and uses thereof | SCHERING CORP | 2015-07-22 | — | — | CN | disclosed |
| US-20150196560-A1 | Inhibitors of Multidrug Resistance Transporter P-Glycoprotein | SOUTHERN METHODIST UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| EP-1896395-B1 | MODIFIED MALONATE DERIVATIVES | MERCK SHARP & DOHME (US) | 2015-07-15 | — | — | EP | disclosed |
| US-9079910-B2 | 5-(1,2,3-triazol-4-yl)-7H-pyrrolo[2,3-D]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-09 | — | — | US | disclosed |
| US-9067938-B2 | Pyrazolopyridinone derivatives as LPA receptor antagonists | MERCK PATENT GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| WO-2015095445-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015094929-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095250-A1 | COMBINATION CANCER THERAPY OF WEE1 AND MTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015094997-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095099-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095444-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095102-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-25 | — | — | US | disclosed |
| CN-104736543-A | 7-azaindol-2,7-naphthyridine derivative for the treatment of tumors | MERCK PATENT GMBH | 2015-06-24 | — | — | CN | disclosed |
| EP-2886126-A1 | CD44 binding peptides | Endosignals Medizintechnik GmbH (DE) | 2015-06-24 | — | — | EP | disclosed |
| EP-2884982-A2 | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2414346-B1 | AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-9062071-B2 | Substituted piperidines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150166486-A1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-18 | — | — | US | disclosed |
| WO-2015085318-A2 | TARGETED ADAPTIVE VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-9051318-B2 | Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-20150152104-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-04 | — | — | US | disclosed |
| US-9045493-B2 | Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives | MERCK PATENT GMBH (DE) | 2015-06-02 | — | — | US | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
| US-20150148351-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2015-05-28 | — | — | US | disclosed |
| US-9029387-B2 | Benzonaphthyridinamines as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2015-05-12 | — | — | US | disclosed |
| US-9029341-B2 | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| CN-101679266-B | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| US-9023865-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150119394-A1 | Insulin-Like Growth Factor-1 Receptor Inhibitors | MERCK SHARP & DOHME CORP. | 2015-04-30 | — | — | US | disclosed |
| EP-2863916-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2863915-A1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2863913-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2863914-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-04-29 | — | — | EP | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| WO-2015051766-A1 | AMIDS SUBSTITUTED INDAZOLE DERIVATIVEES AS PLOY (ADP-RIBOSE) POLYMERASE INHIBITORS | BETTA PHARMACEUTICALS CO., LTD (CN) | 2015-04-16 | — | — | WO | disclosed |
| EP-2683715-B1 | PYRIDO[2,3-B]PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
| EP-2121681-B1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC (CA) | 2015-04-15 | — | — | EP | disclosed |
| CN-102712604-B | Sulfoxide derivatives for treating tumors | MERCK PATENT GMBH | 2015-04-08 | — | — | CN | disclosed |
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999966-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999986-B2 | Pyrrolo [2,3—D] pyrazin—7—ylpyrimidine compounds | MERCK PATENT GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| WO-2015048744-A2 | POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| WO-2015048246-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-04-02 | — | — | WO | disclosed |
| US-8993564-B2 | 7-azaindole derivatives suitable for treatment of cancers | MERCK PATENT GMBH (DE) | 2015-03-31 | — | — | US | disclosed |
| US-8987274-B2 | Macrocycles that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987275-B2 | Indazole compounds and their uses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987301-B2 | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| WO-2015038892-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| US-8981101-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| WO-2015034925-A1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015034928-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| CN-104411324-A | Combination therapy using anti-hyaluronan agents and tumor-targeted taxanes | HALOZYME INC | 2015-03-11 | — | — | CN | disclosed |
| EP-2844261-A2 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | Sirna Therapeutics, Inc. (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8969335-B2 | Benzonitrile derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8962611-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2590946-B1 | Bipyridyl derivatives useful for the treatment of kinase-induced diseases | MERCK PATENT GMBH (DE) | 2015-02-18 | — | — | EP | disclosed |
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| EP-2830625-A1 | INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR INHIBITORS | Merck Sharp & Dohme Corporation (US) | 2015-02-04 | — | — | EP | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20150031670-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| CN-102292339-B | Novel heterocyclic compounds as MetAP-2 inhibitors | MERCK PATENT GMBH | 2015-01-28 | — | — | CN | disclosed |
| EP-2249854-B1 | TREATMENT OF IMMUNOCOMPROMISED CONDITIONS WITH E-SELECTIN ANTAGONIST AND G-CSF | MATER MEDICAL RES INST (AU) | 2015-01-21 | — | — | EP | disclosed |
| US-8927562-B2 | Fused tricyclic inhibitors of mammalian target of rapamycin | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20150005284-A1 | Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives | MERCK PATENT GMBH (DE) | 2015-01-01 | — | — | US | disclosed |
| CN-104245675-A | Cyclic amides as MetAP-2 inhibitors | MERCK PATENT GMBH | 2014-12-24 | — | — | CN | disclosed |
| US-20140371215-A1 | 1-H-Pyrrolo[2,3-b]Pyridine Derivatives | MERCK PATENT GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| EP-2812337-A1 | FURO [3, 2 - B]- AND THIENO [3, 2 - B]PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS | Merck Patent GmbH (DE) | 2014-12-17 | — | — | EP | disclosed |
| WO-2014194975-A1 | A QUINOLINE INHIBITOR OF THE MACROPHAGE STIMULATING 1 RECEPTOR MST1 R | MERCK PATENT GMBH (DE) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014197411-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-12-11 | — | — | WO | disclosed |
| CN-102272121-B | Polymorphic forms of 3- (1- {3- [5- (1-methyl-piperidin-4-ylmethoxy) -pyrimidin-2-yl ] -benzyl } -6-oxo-1, 6-dihydro-pyridazin-3-yl) -benzonitrile hydrochloride and processes for their preparation | MERCK PATENT GMBH | 2014-12-10 | — | — | CN | disclosed |
| US-8906954-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-12-04 | — | — | US | disclosed |
| US-8900565-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901142-B2 | Fused tricyclic compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140349968-A1 | Compositions and Methods for Treating Cancer | ARIAD PHARMACEUTICALS, INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350046-A1 | PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| EP-2805945-A1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD Italia S.r.l. (IT) | 2014-11-26 | — | — | EP | disclosed |
| CN-102666544-B | Pyrrolo[2,3-d]pyrazin-7-yl pyrimidine compounds | MERCK PATENT GMBH | 2014-11-26 | — | — | CN | disclosed |
| US-8895575-B2 | 1 H-pyrrolo[2,3-b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895535-B2 | Pyrrolidinones as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-20140343071-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. | 2014-11-20 | — | — | US | disclosed |
| US-20140343126-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2014-11-20 | — | — | US | disclosed |
| US-20140343075-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| EP-2099442-B1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS INC (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| EP-2611808-B1 | PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| CN-101693672-B | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2014-11-12 | — | — | CN | disclosed |
| US-8883801-B2 | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| WO-2014179154-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-06 | — | — | WO | disclosed |
| CN-104136410-A | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS INC | 2014-11-05 | — | — | CN | disclosed |
| EP-2797875-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | Pharmacyclics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140323481-A1 | 3-CYANOARYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323482-A1 | SUBSTITUTED PIPERIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-30 | — | — | US | disclosed |
| WO-2014176210-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014176216-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIMIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | WO | disclosed |
| EP-2793890-A1 | SUBSTITUTED PIPERIDINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140315916-A1 | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2014-10-23 | — | — | US | disclosed |
| CN-102481361-B | Compositions and methods for treating cancer | MERCK SHARP & DOHME CORP. (US) | 2014-10-22 | — | — | CN | disclosed |
| US-8865715-B2 | Substituted 7-(1,2,3-Triazol-4-yl)-pyrrolo[2,3-b]pyrazines | MERCK PATENT GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| EP-2170339-B1 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2104669-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8859775-B2 | Pyrazolopyridinone derivatives as LPA receptor antagonists | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859581-B2 | Azaheterocyclic compounds as kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | disclosed |
| CN-104093722-A | Furo [3,2-b]-thieno and [3,2-b]pyridine derivatives as tbk1 and ikk inhibitors | MERCK PATENT GMBH | 2014-10-08 | — | — | CN | disclosed |
| US-8852590-B2 | Compositions and methods for treating cancer | MERCK SHARP & DOHME CORP. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-20140296203-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140296268-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2014-10-02 | — | — | US | disclosed |
| US-8846694-B2 | Pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846657-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| WO-2014152211-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8841324-B2 | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| US-8835623-B2 | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| WO-2014132100-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2014-09-04 | — | — | WO | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
| EP-2770987-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2220073-B1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA SRL (IT) | 2014-09-03 | — | — | EP | disclosed |
| EP-2771008-A1 | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822476-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822475-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2014-09-02 | — | — | US | disclosed |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140228340-A1 | BENZONITRILE DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228379-A1 | Pyrido-Pyrimidine Derivatives | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| WO-2014123882-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014120748-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| US-20140221314-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8796460-B2 | Compounds for inhibiting KSP kinesin activity | Mercky Sharp & Dohme Corp. (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2014113942-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014116504-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114185-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014113932-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| EP-2373640-B1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2014-07-30 | — | — | EP | disclosed |
| EP-2303269-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8791111-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20140206681-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-07-24 | — | — | US | disclosed |
| CN-103946223-A | 3-cyanaryl-1h-pyrazolo[2.3-b]pyridine derivatives | MERCK PATENT GMBH | 2014-07-23 | — | — | CN | disclosed |
| EP-2755482-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Merck Sharp & Dohme Corp. (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20140200221-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2014-07-17 | — | — | US | disclosed |
| CN-103930416-A | Benzonitrile derivatives as kinase inhibitors | MERCK PATENT GMBH | 2014-07-16 | — | — | CN | disclosed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140194404-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | MERCK SHARP & DOHME LLC | 2014-07-10 | — | — | US | disclosed |
| US-20140187551-A1 | 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS | MERCK PATENT GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8765747-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | MERCK SHARP & DOHME LLC | 2014-06-26 | — | — | US | disclosed |
| WO-2014100065-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100071-A2 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100314-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| CN-101163717-B | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases | HALOZYME INC | 2014-06-25 | — | — | CN | disclosed |
| CN-102307993-B | Extended soluble ph20 polypeptides and uses thereof | HALOZYME INC | 2014-06-25 | — | — | CN | disclosed |
| EP-2049494-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140171456-A1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2742043-A1 | PYRIDO-PYRIMIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-8754097-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| WO-2014085216-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2736338-A1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-06-04 | — | — | EP | disclosed |
| CN-102414211-B | 3- ([1,2,3] triazol-4-yl) pyrrolo [2,3-b ] pyridine derivatives | MERCK PATENT GMBH | 2014-06-04 | — | — | CN | disclosed |
| US-20140148457-A1 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148474-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-05-29 | — | — | US | disclosed |
| EP-2734529-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20140142097-A1 | PYRIDINE-AND PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| WO-2014074421-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-05-15 | — | — | WO | disclosed |
| CN-102365271-B | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH | 2014-05-14 | — | — | CN | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| CN-103764651-A | 7-azaindole derivatives suitable for treatment of cancers | MERCK PATENT GMBH | 2014-04-30 | — | — | CN | disclosed |
| US-8710058-B2 | Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof | MERCK PATENT GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| WO-2014062454-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-04-24 | — | — | WO | disclosed |
| CN-103748086-A | Pyridine-and pyrazine derivatives | MERCK PATENT GMBH | 2014-04-23 | — | — | CN | disclosed |
| US-8703784-B2 | Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| CN-102369195-B | Autotaxin inhibitors | MERCK PATENT GMBH | 2014-04-16 | — | — | CN | disclosed |
| EP-2717882-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF ISOCITRATE DEHYDROGENASE (IDH1) GENE EXPRESSION | Merck Sharp & Dohme Corp. (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2247185-B1 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140100250-A1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-04-10 | — | — | US | disclosed |
| US-20140100221-A1 | 1H-Pyrrolo[2,3-b]Pyridine Derivatives | MERCK PATENT GMBH (DE) | 2014-04-10 | — | — | US | disclosed |
| CN-103717609-A | Tricyclic inhibitors of poly (ADP-ribose) polymerase | NEWGEN THERAPEUTICS INC | 2014-04-09 | — | — | CN | disclosed |
| CN-103694258-A | Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity | SCHERING CORP | 2014-04-02 | — | — | CN | disclosed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| EP-2706852-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2706853-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2707357-A1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-03-19 | — | — | EP | disclosed |
| CN-101754965-B | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG | 2014-03-19 | — | — | CN | disclosed |
| US-20140072555-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2014-03-13 | — | — | US | disclosed |
| EP-1828171-B1 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2014-03-12 | — | — | EP | disclosed |
| EP-2341775-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2014-03-12 | — | — | EP | disclosed |
| CN-102264729-B | Polymorphic forms of 6- (1-methyl-1H-pyrazol-4-yl) -2- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl ] -benzyl } -2H-pyridazin-3-one dihydrogenphosphate and processes for their preparation | MERCK PATENT GMBH | 2014-03-05 | — | — | CN | disclosed |
| EP-2701507-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | Merck Sharp & Dohme Corp. (US) | 2014-03-05 | — | — | EP | disclosed |
| CN-103619172-A | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME | 2014-03-05 | — | — | CN | disclosed |
| US-8664236-B2 | 1H-pyrrolo[2,3 b]-pyridine derivatives | MERCK PATENT GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| WO-2014031438-A2 | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2699567-A1 | INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-02-26 | — | — | EP | disclosed |
| CN-102471317-B | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH | 2014-02-26 | — | — | CN | disclosed |
| CN-103596938-A | Thiazole derivatives | MERCK PATENT GMBH | 2014-02-19 | — | — | CN | disclosed |
| EP-2698157-A1 | Method of treatment using fatty acid synthesis inhibitors | Merck Sharp & Dohme Corp. (US) | 2014-02-19 | — | — | EP | disclosed |
| US-20140045832-A1 | Insulin-Like Growth Factor-1 Receptor Inhibitors | Piramal Enterprises Limited (IN) | 2014-02-13 | — | — | US | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| CN-101903365-B | Spiro-condensed 1,3, 4-thiadiazole derivatives for inhibiting KSP kinesin activity | MERCK SHARP & DOHME | 2014-02-05 | — | — | CN | disclosed |
| EP-2688872-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | Merck Sharp & Dohme Corp. (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2683715-A1 | PYRIDO [2, 3 - B]PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | Merck Patent GmbH (DE) | 2014-01-15 | — | — | EP | disclosed |
| CN-103502247-A | 7-azaindole derivatives | MERCK PATENT GMBH | 2014-01-08 | — | — | CN | disclosed |
| US-20140004174-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| WO-2013192088-A1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-12-27 | — | — | WO | disclosed |
| WO-2013192125-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-12-27 | — | — | WO | disclosed |
| WO-2013192128-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-12-27 | — | — | WO | disclosed |
| WO-2013192098-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-12-27 | — | — | WO | disclosed |
| US-20130345227-A1 | PYRIDO [2, 3 - B] PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | MERCK PATENT GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-20130344476-A1 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-26 | — | — | US | disclosed |
| EP-2211620-B1 | 3-PYRAZIN SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS JANUS KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | MERCK SHARP & DOHME (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8614221-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| EP-2152700-B1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-20130324588-A1 | RNA Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (siNA) | BANK OF AMERICA, N.A. | 2013-12-05 | — | — | US | disclosed |
| CN-103420988-A | Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp) | ANGELETTI P IST RICHERCHE BIO | 2013-12-04 | — | — | CN | disclosed |
| US-8598184-B2 | Protein kinase inhibitors | TIGER PHARMATECH (US) | 2013-12-03 | — | — | US | disclosed |
| US-8598153-B2 | Method of treatment using fatty acid synthesis inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8592459-B2 | Substituted benzimidazoles and methods of their use | NOVARTIS AG (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| CN-103403005-A | 5- ([1,2,3] -triazol-4-yl) -7H-pyrrolo [2,3-d ] pyrimidine derivatives | MERCK PATENT GMBH | 2013-11-20 | — | — | CN | disclosed |
| US-8586599-B2 | Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof | MERCK PATENT GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| CN-103391938-A | Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses | MERCK PATENT GMBH | 2013-11-13 | — | — | CN | disclosed |
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8580792-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-11-12 | — | — | US | disclosed |
| WO-2013165816-A2 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | MERCK SHARP & DOHME CORP. (US) | 2013-11-07 | — | — | WO | disclosed |
| US-20130296274-A1 | PYRROLIDINONES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-11-07 | — | — | US | disclosed |
| CN-101679425-B | 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine and its uses in treating cancer and AIDS | MERCK PATENT GMBH | 2013-11-06 | — | — | CN | disclosed |
| CN-103381267-A | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | HALOZYME INC | 2013-11-06 | — | — | CN | disclosed |
| US-8575163-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20130289017-A1 | 5 (1,2,3-TRIAZOL-4-YL)-7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130287763-A1 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2013-10-31 | — | — | US | disclosed |
| EP-2654748-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-10-30 | — | — | EP | disclosed |
| CN-101855221-B | Pyridazinone derivatives as PARP inhibitors | ANGELETTI P IST RICHERCHE BIO | 2013-10-30 | — | — | CN | disclosed |
| US-20130281474-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MERCK SHARP & DOHME CORP. (US) | 2013-10-24 | — | — | US | disclosed |
| CN-101600706-B | Inhibitors of akt activity | MERCK SHARP & DOHME | 2013-10-16 | — | — | CN | disclosed |
| CN-102056926-B | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH | 2013-10-16 | — | — | CN | disclosed |
| US-8557977-B2 | 4 (pyrrolopyridinyl)pyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552001-B2 | Sulfoxide derivatives for the treatment of tumors | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8551489-B2 | Methods for the treatment of cancers | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130261125-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-10-03 | — | — | US | disclosed |
| WO-2013148227-A1 | INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546390-B2 | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| CN-101674820-B | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy | PHARMACYCLICS INC | 2013-09-25 | — | — | CN | disclosed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20130245355-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-8536193-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP | 2013-09-12 | — | — | US | disclosed |
| US-8530650-B2 | 2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer | MERCK PATENT GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130231519-A1 | 1H-Pyrrolo[2,3 b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| CN-103282497-A | RNA interference-mediated suppression of Hepatitis B Virus (HBV) gene expression using short interfering nucleic acids (siNA) | MERCK SHARP & DOHME | 2013-09-04 | — | — | CN | disclosed |
| EP-2632268-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2632462-A1 | NOVEL HETEROARYL-CARBOXAMIDE DERIVATIVES AS PDK1 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2632263-A1 | NOVEL THIAZOLE-CARBOXAMIDE DERIVATIVES AS PDK1 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2632472-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8524732-B2 | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| US-20130225591-A1 | IMIDOTHIAZOLE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-29 | — | — | US | disclosed |
| CN-101432281-B | 6-0-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG | 2013-08-28 | — | — | CN | disclosed |
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518907-B2 | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217756-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) | MERCK SHARP & DOHME CORP. (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2013117285-A1 | FURO [3, 2 - B] - AND THIENO [3, 2 - B] PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-15 | — | — | WO | disclosed |
| EP-2626072-A1 | Piperidine and piperazine derivatives as autotaxin inhibitors | Merck Patent GmbH (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2626067-A1 | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy | PHARMACYCLICS, INC. (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2361250-B1 | NOVEL POLYMORPHIC FORMS OF 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-{3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2013-08-07 | — | — | EP | disclosed |
| EP-2621925-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2623101-A1 | Piperidine and piperazine derivatives as autotaxin inhibitors | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| CN-103232381-A | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2013-08-07 | — | — | CN | disclosed |
| EP-2623491-A2 | Piperidine and piperazine derivatives as autotaxin inhibitors | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-8501450-B2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | THE CHANCELLORS, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-08-01 | — | — | US | disclosed |
| CN-103228657-A | 3-heteroaryl-substituted pyrrolo [2,3-b ] pyridine derivatives as PDK1 inhibitors | MERCK PATENT GMBH | 2013-07-31 | — | — | CN | disclosed |
| EP-2299825-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2620150-A2 | 2-Amido Thiazole Based Inhibitors of ATP-Utilizing Enyzmes | Genentech, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8497283-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| EP-2616451-A1 | NOVEL THIAZOL-CARBOXIMIDE DERIVATIVES AS PDK1 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-1951748-B1 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMA (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2615916-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130184287-A1 | INDAZOLE COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| EP-2613782-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-17 | — | — | EP | disclosed |
| CN-101578279-B | Amide substituted indazoles as poly (ADP ribose) polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO | 2013-07-17 | — | — | CN | disclosed |
| CN-103205407-A | Extended soluble ph20 polypeptides and uses thereof | HALOZYME INC | 2013-07-17 | — | — | CN | disclosed |
| CN-101203495-B | Benzocycloheptapyridine compounds as inhibitors of receptor tyrosine kinase MET | MERCK SHARP & DOHME | 2013-07-17 | — | — | CN | disclosed |
| EP-2611450-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611808-A1 | PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2013-07-10 | — | — | EP | disclosed |
| WO-2013101600-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| EP-2231143-B1 | 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2405756-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2608668-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | Merck Sharp & Dohme Corp. (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2608669-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-03 | — | — | EP | disclosed |
| CN-103189378-A | Pyrazolopyridinone derivatives as LPA receptor antagonists | MERCK PATENT GMBH | 2013-07-03 | — | — | CN | disclosed |
| US-20130165450-A1 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors | TSUI HON-CHUNG (CN) | 2013-06-27 | — | — | US | disclosed |
| US-20130165478-A1 | PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-27 | — | — | US | disclosed |
| US-20130165449-A1 | Compounds and Method for Treatment of Cancer | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-06-27 | — | — | US | disclosed |
| WO-2013096150-A1 | SUBSTITUTED PIPERIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-27 | — | — | WO | disclosed |
| CN-103180320-A | 1H-pyrrolo [2,3-b ] pyridine derivatives | MERCK PATENT GMBH | 2013-06-26 | — | — | CN | disclosed |
| EP-2606134-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130156727-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| CN-103168042-A | 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate | MERCK PATENT GMBH | 2013-06-19 | — | — | CN | disclosed |
| US-8466193-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130150433-A1 | RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) Gene Expression Using Short Interfering Nucleic Acid (siNA) | BANK OF AMERICA, N.A. | 2013-06-13 | — | — | US | disclosed |
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150353-A1 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin | MERCK SHARP & DOHME LLC | 2013-06-13 | — | — | US | disclosed |
| CN-103153951-A | Pyrrolidones as MetAP-2 inhibitors | MERCK PATENT GMBH | 2013-06-12 | — | — | CN | disclosed |
| EP-2601293-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | Merck Sharp & Dohme Corp. (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8461189-B2 | Pyridyl derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| EP-2598168-A2 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130137690-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| US-20130137752-A1 | RNA Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (siNA) | BANK OF AMERICA, N.A. | 2013-05-30 | — | — | US | disclosed |
| US-20130131041-A1 | SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2593107-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2590946-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | Merck Patent GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| EP-1494676-B1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8436185-B2 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2013063214-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013062923-A1 | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-2414330-B1 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-05-01 | — | — | EP | disclosed |
| EP-2585461-A1 | 2,4- DIARYL - SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | Merck Patent GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| EP-2584903-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| CN-103080093-A | Indazole compounds and their uses | DANA FARBER CANCER INST INC | 2013-05-01 | — | — | CN | disclosed |
| US-8431569-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | LIANG PENG (CN) | 2013-04-25 | — | — | US | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2013059582-A2 | SMALL MOLECULE INHIBITORS OF HISTONE DEACTEYLASES | NUPOTENTIAL, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| CN-1869061-B | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2013-04-24 | — | — | CN | disclosed |
| CN-103068980-A | RNA interference mediated inhibition of the catenin (cadherin-associated protein), beta 1(CTNNB1) gene expression using short interfering nucleic acids (siNA) | MERCK SHARP & DOHME | 2013-04-24 | — | — | CN | disclosed |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MERCK SHARP & DOHME LLC | 2013-04-18 | — | — | US | disclosed |
| CN-103052633-A | Amids Substituted Indazole Derivativees As Ploy(adp-ribose)polymerase Inhibitors | ZHEJIANG BETA PHARMA INC | 2013-04-17 | — | — | CN | disclosed |
| EP-2579872-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8420643-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-04-16 | — | — | US | disclosed |
| US-8420820-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420695-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8415346-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-1898903-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2013039854-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-1991226-B1 | INHIBITORS OF HISTONE DEACETYLASE | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | disclosed |
| CN-102971293-A | Bipyridine derivatives for the treatment of kinase-induced diseases | MERCK PATENT GMBH | 2013-03-13 | — | — | CN | disclosed |
| CN-101633636-B | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2013-03-13 | — | — | CN | disclosed |
| CN-101415686-B | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO | 2013-03-13 | — | — | CN | disclosed |
| CN-102958930-A | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH | 2013-03-06 | — | — | CN | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389553-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389570-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2352732-B1 | 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | MERCK PATENT GMBH (DE) | 2013-02-20 | — | — | EP | disclosed |
| WO-2013022519-A1 | PYRIDO-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-02-14 | — | — | WO | disclosed |
| EP-2278969-B1 | Inhibitors of Janus kinases | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8367675-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-02-05 | — | — | US | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2013016164-A1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-31 | — | — | WO | disclosed |
| US-8362030-B2 | Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2013-01-29 | — | — | US | disclosed |
| US-8362075-B2 | Cyclohexyl sulphones for treatment of cancer | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2547661-A2 | INDAZOLE COMPOUNDS AND THEIR USES | Dana-Farber Cancer Institute, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-8354413-B2 | Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) | Istituto di Ricerche di Biologia Molecolare P. Angeletti, S.R.L. (IT) | 2013-01-15 | — | — | US | disclosed |
| US-20130012505-A1 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-10 | — | — | US | disclosed |
| CN-101374515-B | Inhibitors of akt activity | MERCK SHARP & DOHME | 2013-01-09 | — | — | CN | disclosed |
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349825-B2 | Spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| CN-102858767-A | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME | 2013-01-02 | — | — | CN | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-1945617-B1 | HISTONE DEACETYLASE INHIBITORS WITH ARYL-PYRAZOLYL MOTIFS | MERCK SHARP & DOHME (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8338416-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYLICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| EP-2534145-A2 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | Kinagen, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2168578-B1 | Thiazole based inhibitors of ATP-utilizing enzymes | GENENTECH INC (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2012170284-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF ISOCITRATE DEHYDROGENASE (IDH1) GENE EXPRESSION | MERCK SHARP & DOHME CORP. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120316162-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| CN-101253168-B | Substituted benzimidazoles as kinase inhibitors | NOVARTIS AG | 2012-12-12 | — | — | CN | disclosed |
| CN-102822171-A | Benzonaphthyridinamines as autotaxin inhibitors | MERCK PATENT GMBH | 2012-12-12 | — | — | CN | disclosed |
| CN-101809001-B | Imidazole derivatives | MERCK PATENT GMBH | 2012-12-12 | — | — | CN | disclosed |
| US-8329722-B2 | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329907-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| WO-2012166983-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-8324389-B2 | Solid forms of a Raf kinase inhibitor | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| WO-2012161879-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012161877-A1 | PYRIDINE-AND PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012158197-A2 | COMPOUNDS USEFUL AS AKT/PKB MODULATORS AND USES THEREOF | LYNDOR BIOSCIENCES L.L.C. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012154518-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154519-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154520-A1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289481-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. | 2012-11-15 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8304416-B2 | Chromenone derivatives | MERCK PATENT GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| WO-2012148792-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-2032141-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012145471-A1 | INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270871-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270880-A1 | PYRROLO [2,3-D] PYRAZIN-7-YLPYRIMIDINE COMPOUNDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | disclosed |
| EP-2513059-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293891-B2 | 4 (pyrrolopyridinyl)pyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20120264999-A1 | 4 (PYRROLOPYRIDINYL)PYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| EP-2166846-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8288407-B2 | Substituted naphthyridine compounds as inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120252806-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2012-10-04 | — | — | US | disclosed |
| CN-102712604-A | Sulfoxide derivatives for treating tumors | MERCK PATENT GMBH | 2012-10-03 | — | — | CN | disclosed |
| US-8278335-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| WO-2012129258-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | MERCK SHARP & DOHME CORP. (US) | 2012-09-27 | — | — | WO | disclosed |
| US-8268845-B2 | Tetrahydro- and dihydroquinazolinones | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268827-B2 | Pyridazinone derivatives as PARP inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-09-18 | — | — | US | disclosed |
| WO-2012119690-A1 | PYRIDO [2, 3 - B] PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | MERCK PATENT GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
| CN-102666544-A | Pyrrolo[2,3-d]pyrazin-7-yl pyrimidine compounds | MERCK PATENT GMBH | 2012-09-12 | — | — | CN | disclosed |
| EP-2496234-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-09-12 | — | — | EP | disclosed |
| CN-102666538-A | Pyrrolopyridinyl-pyrimidin-2-ylamine derivatives | MERCK PATENT GMBH | 2012-09-12 | — | — | CN | disclosed |
| US-20120225912-A1 | NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF | ALBERTA HEALTH SERVICES (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-06 | — | — | US | disclosed |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120220611-A1 | 1,3-BENZOXAZOLYL DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | disclosed |
| EP-2490693-A1 | PYRAZOLO [3,4-b]PYRIDIN-4-ONE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252800-B2 | Protein tyrosine kinase inhibitors | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2012-08-28 | — | — | US | disclosed |
| EP-2488028-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| CN-102638981-A | Substituted piperidines that increase p53 activity and uses thereof | SCHERING CORP | 2012-08-15 | — | — | CN | disclosed |
| US-8242103-B2 | Sulphamides for treatment of cancer | MERCK SHARP & DOHME LIMITED (GB) | 2012-08-14 | — | — | US | disclosed |
| US-8242128-B2 | 1,3-benzoxazolyl derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2012-08-14 | — | — | US | disclosed |
| US-20120202827-A1 | SULFOXIDE DERIVATIVES FOR THE TREATMENT OF TUMORS | Merck Patent Gesellschaft mit beschrankter Hafung (DE) | 2012-08-09 | — | — | US | disclosed |
| EP-2200612-B1 | INHIBITORS OF JANUS KINASES | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120195887-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-08-02 | — | — | US | disclosed |
| EP-2480076-A1 | IMIDOTHIAZOLE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120190747-A1 | METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-26 | — | — | US | disclosed |
| EP-1954290-B1 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | disclosed |
| CN-102596200-A | Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors | MERCK PATENT GMBH | 2012-07-18 | — | — | CN | disclosed |
| US-8222269-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2470499-A1 | NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF | Alberta Health Services (CA) | 2012-07-04 | — | — | EP | disclosed |
| WO-2012087772-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207169-B2 | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D | MSD K.K. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207186-B2 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8202882-B2 | 5-cyanothienopyridines for the treatment of tumours | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-06-19 | — | — | US | disclosed |
| EP-1678202-B1 | HCV NS3-NS4A PROTEASE RESISTANCE MUTANTS | VERTEX PHARMA (US) | 2012-06-13 | — | — | EP | disclosed |
| CN-102481361-A | Compositions and methods for treating cancer | MERCK SHARP & DOHME | 2012-05-30 | — | — | CN | disclosed |
| CN-102480966-A | Fused heterocyclic compounds and uses thereof | NOVARTIS AG | 2012-05-30 | — | — | CN | disclosed |
| US-8188084-B2 | Pyridinone and pyridazinone derivatives as inhibitors of poly (ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-05-29 | — | — | US | disclosed |
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | FINSINGER DIRK (DE) | 2012-05-24 | — | — | US | disclosed |
| CN-102471343-A | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH | 2012-05-23 | — | — | CN | disclosed |
| CN-102471317-A | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH | 2012-05-23 | — | — | CN | disclosed |
| US-8183245-B2 | Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1 | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115852-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-8173689-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173629-B2 | Method of treatment using fatty acid synthesis inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2012058176-A1 | NOVEL HETEROARYL-CARBOXAMIDE DERIVATIVES AS PDK1 INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058174-A1 | NOVEL THIAZOLE-CARBOXAMIDE DERIVATIVES AS PDK1 INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058127-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058210-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| EP-2445916-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | Merck Patent GmbH (DE) | 2012-05-02 | — | — | EP | disclosed |
| US-8168658-B2 | Inhibitors of histone deacetylase | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168652-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120101095-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-04-26 | — | — | US | disclosed |
| EP-2440058-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | Dana-Farber Cancer Institute, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8158799-B2 | Hydroxyquinoline derivatives | Merck Patent Gesellschaft MIT Meschraenkter Haftung (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8158825-B2 | Modified malonate derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158152-B2 | Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets | SCIDOSE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2012047570-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | SCHERING CORPORATION (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012047569-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | SCHERING CORPORATION (US) | 2012-04-12 | — | — | WO | disclosed |
| CN-102414211-A | 3- ([1,2,3] triazol-4-yl) pyrrolo [2,3-b ] pyridine derivatives | MERCK PATENT GMBH | 2012-04-11 | — | — | CN | disclosed |
| US-20120077810-A1 | Inhibitors Of AKT Activity | MERCK SHARP & DOHME LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120076784-A1 | HIGHLY CONCENTRATED, LIQUID FORMULATIONS OF ANTI-EGFR ANTIBODIES | MATHEUS SUSANNE (DE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077820-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-03-29 | — | — | US | disclosed |
| CN-102391222-A | Novel hydroxamates as therapeutic agents | PHARMACYCLICS INC | 2012-03-28 | — | — | CN | disclosed |
| US-20120070370-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-22 | — | — | US | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012036974-A1 | NOVEL THIAZOL-CARBOXIMIDE DERIVATIVES AS PDK1 INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-2430030-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | Schering Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1320540-B9 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMA (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1888050-B1 | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer | MERCK SHARP & DOHME (GB) | 2012-03-21 | — | — | EP | disclosed |
| US-8138191-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-03-20 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120064032-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2012030685-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030633-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028243-A1 | PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-08 | — | — | US | disclosed |
| CN-102369195-A | Autotaxin inhibitors | MERCK PATENT GMBH | 2012-03-07 | — | — | CN | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2012027234-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | SCHERING CORPORATION (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027236-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | SCHERING CORPORATION (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027239-A1 | NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | SCHERING CORPORATION (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027240-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | SCHERING CORPORATION (US) | 2012-03-01 | — | — | WO | disclosed |
| CN-102365271-A | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH | 2012-02-29 | — | — | CN | disclosed |
| WO-2012024170-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-8119652-B2 | Aryl-fused spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119685-B2 | Disubstituted aniline compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2012021383-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF MITOGEN-ACTIVATED PROTEIN KINASE 1 (MAPK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-8114882-B2 | Antitumor agents; kinase inhibitors; angiogenesis inhibitors; arteriosclerosis ; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| WO-2012018754-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | MERCK SHARP & DOHME CORP. (US) | 2012-02-09 | — | — | WO | disclosed |
| EP-2413932-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2414330-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | Merck Patent GmbH (DE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2414346-A1 | AUTOTAXIN INHIBITORS | Merck Patent GmbH (DE) | 2012-02-08 | — | — | EP | disclosed |
| US-8110583-B2 | treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle | MERCK PATENT GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| WO-2012015741-A2 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20120027757-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MEDINOL LTD. (IL) | 2012-02-02 | — | — | US | disclosed |
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
| US-8101603-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| WO-2012006958-A1 | AMIDS SUBSTITUTED INDAZOLE DERIVATIVEES AS PLOY(ADP-RIBOSE)POLYMERASE INHIBITORS | ZHEJIANG BETA PHARMA INC. (CN) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| EP-2406250-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-2405756-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-8097727-B2 | N,N′-diphenylurea derivatives which are suitable as kinase inhibitors | MERCK PATENT GMBH (DE) | 2012-01-17 | — | — | US | disclosed |
| WO-2012003912-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | MERCK PATENT GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| CN-102304110-A | Hydroxamates as therapeutic agents | AXYS PHARM INC | 2012-01-04 | — | — | CN | disclosed |
| US-20110319443-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-12-29 | — | — | US | disclosed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | disclosed |
| CN-102292339-A | Novel heterocyclic compounds as MetAP-2 inhibitors | — | 2011-12-21 | — | — | CN | disclosed |
| US-8080573-B2 | Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (hdac) inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-12-20 | — | — | US | disclosed |
| CN-102272121-A | Novel polymorphic forms of 3- (1- {3- [5- (1-methyl-piperidin-4-ylmethoxy) -pyrimidin-2-yl ] -benzyl } -6-oxo-1, 6-dihydro-pyridazin-3-yl) -benzonitrile hydrochloride and processes for their preparation | — | 2011-12-07 | — | — | CN | disclosed |
| EP-2392590-A2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392588-A2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392589-A2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-07 | — | — | EP | disclosed |
| US-8071623-B2 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA | 2011-12-06 | — | — | US | disclosed |
| CN-102264729-A | New polymorphic form of 6- (1-methyl-1H-pyrazol-4-yl) -2- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl ] -benzyl } -2H-pyridazin-3-one dihydrogenphosphate and process for preparing same | — | 2011-11-30 | — | — | CN | disclosed |
| CN-101346383-B | Triazole derivatives | MERCK PATENT GMBH (DE) | 2011-11-30 | — | — | CN | disclosed |
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| US-8063040-B2 | Triazabenzo[E]azulene derivatives for the treatment of tumors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-22 | — | — | US | disclosed |
| US-20110281887-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2011-11-17 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110269767-A1 | Novel Polymorphic Forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile Hydrochloride Salt and Processes of Manufacturing Thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2011130921-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133733-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| CN-102227426-A | Benzonaphtyridine compounds used as inhibitors of autotaxin | MERCK PATENT GMBH | 2011-10-26 | — | — | CN | disclosed |
| WO-2011130065-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | MERCK SHARP & DOHME CORP. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110257180-A1 | Novel Polymorphic Forms of 6-(1-methyl-1H-pyrazol-4-yl)-2--2H-pyridazin-3-one Dihydrogenphosphate and Processes of Manufacturing thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-10-20 | — | — | US | disclosed |
| EP-2374464-A2 | HCV N3S-NS4A protease inhibition | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-1909783-B1 | ILLUDIN ANALOGS USEFUL AS ANTICANCER AGENTS | UNIV CALIFORNIA (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2373640-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | Merck Patent GmbH (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-8034815-B2 | Imidazol-1-yl-(4-pyridin-2-yl-piperazin-1-yl)-methanethione; Critical Outcome Technologies' Iead compound (COTI); kinase inhibitor; anticarcinogenic agent; especially small cell lung cancer; cervical, ovarian, skin, prostate, breast, colorectal, head, neck, or kidney cancer, sarcoma, leukemia | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2011-10-11 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| US-20110244549-A1 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2371839-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110237583-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-09-29 | — | — | US | disclosed |
| EP-2368901-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368877-A1 | Chiral intermediates for the preparation of peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368878-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-1926722-B1 | SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-8026371-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026260-B2 | Histone deacetylase inhibitors with aryl-pyrazolyl-motifs | MERCK SHARP & DOHME CORP. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026265-B2 | Heterocycle substituted ketone derivatives as histone deacetylase (HDAC) inhibitors | Istituto de Ricerche di Biologia Molecolare P. Angeletti SpA. (IT) | 2011-09-27 | — | — | US | disclosed |
| WO-2011115725-A2 | INDAZOLE COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2134346-B1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-1896421-B1 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-09-08 | — | — | US | disclosed |
| US-20110218176-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS-SPRING BARBARA BROOKE | 2011-09-08 | — | — | US | disclosed |
| EP-2361250-A1 | NOVEL POLYMORPHIC FORMS OF 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-{3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE AND PROCESSES OF MANUFACTURING THEREOF | Merck Patent GmbH (DE) | 2011-08-31 | — | — | EP | disclosed |
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207720-A1 | QUINOLIN-4-ONE AND 4-OXODIHYRDOCINNOLINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2011-08-25 | — | — | US | disclosed |
| CN-102160891-A | Hcv ns3-ns4a protease inhibition | VERTEX PHARMA | 2011-08-24 | — | — | CN | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003643-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110201657-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-08-18 | — | — | US | disclosed |
| EP-1896422-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110195965-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | FINSINGER DIRK | 2011-08-11 | — | — | US | disclosed |
| WO-2011097594-A2 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | KINAGEN, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| EP-2352732-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO Ý4, 3-D¨PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | Merck Patent GmbH (DE) | 2011-08-10 | — | — | EP | disclosed |
| WO-2011090935-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-7981874-B2 | Phosphorus derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-07-14 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| EP-2341775-A1 | INHIBITORS OF JANUS KINASES | Merck & Co., Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-7977374-B2 | Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-07-12 | — | — | US | disclosed |
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110150757-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-06-23 | — | — | US | disclosed |
| WO-2011075383-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-2336120-A1 | Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) | 2011-06-22 | — | — | EP | disclosed |
| CN-101115742-B | Heterocycle derivatives as histone deacetylase (hdac) inhibitors | ANGELETTI P IST RICHERCHE BIO | 2011-06-22 | — | — | CN | disclosed |
| WO-2011071892-A2 | SURFACES FOR CONTROLLED BIOADHESION, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-1622616-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7960516-B2 | Solid forms of anti-EGFR antibodies | MERCK PATENT GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20110136830-A1 | CHROMENONE DERIVATIVES | MUJICA-FERNAUD TERESA | 2011-06-09 | — | — | US | disclosed |
| US-20110130361-A1 | SILICON DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | GRIMM JONATHAN | 2011-06-02 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130393-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-06-02 | — | — | US | disclosed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110117078-A1 | Methods for the Treatment of Cancers | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2011-05-19 | — | — | US | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7943608-B2 | Diazepinoes | MERCK PATENT GMBH (DE) | 2011-05-17 | — | — | US | disclosed |
| US-20110112081-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-05-12 | — | — | US | disclosed |
| WO-2011054433-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-05-12 | — | — | WO | disclosed |
| EP-2318406-A1 | THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS | Critical Outcome Technologies, Inc. (CA) | 2011-05-11 | — | — | EP | disclosed |
| CN-102056926-A | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH | 2011-05-11 | — | — | CN | disclosed |
| US-20110098268-A1 | SPIROCYCLIC COMPOUNDS | MERCK & CO., INC (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011049722-A1 | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092527-A1 | 4 (Pyrrolopyridinyl)pyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092511-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-21 | — | — | US | disclosed |
| WO-2011046771-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | SCHERING CORPORATION (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-2310384-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2011044072-A1 | COMBINATION OF RAF-265 AND AN ACTIVATOR OF AMPK FOR USE IN THE TREATMENT OF A PROLIFERATIVE DISEASE | NOVARTIS AG (CH) | 2011-04-14 | — | — | WO | disclosed |
| US-20110086006-A1 | HCV NS3-NS4 Protease Resistance Mutants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-14 | — | — | US | disclosed |
| CN-102017525-A | Inhibitors of checkpoint kinases | MERCK & CO INC | 2011-04-13 | — | — | CN | disclosed |
| CN-102014902-A | Inhibitors of checkpoint kinases | MERCK & CO INC | 2011-04-13 | — | — | CN | disclosed |
| EP-2307425-A1 | IMIDAZOTHIADIAZOLES DERIVATIVES | Merck Patent GmbH (DE) | 2011-04-13 | — | — | EP | disclosed |
| CN-102015724-A | Thienopyrimidines | MERCK PATENT GMBH | 2011-04-13 | — | — | CN | disclosed |
| CN-102010416-A | Substituted tetrahydroquinolines | MERCK PATENT GMBH | 2011-04-13 | — | — | CN | disclosed |
| CN-102014631-A | Tyrosine kinase inhibitors | TIGER PHARMATECH | 2011-04-13 | — | — | CN | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110081409-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2011-04-07 | — | — | US | disclosed |
| EP-2303269-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011037780-A1 | IMIDOTHIAZOLE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-03-31 | — | — | WO | disclosed |
| EP-2299825-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2299816-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-1558586-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7915416-B2 | Tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| EP-2109608-B1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2011-03-23 | — | — | EP | disclosed |
| US-7910561-B2 | Cancer; such as 3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridin-5(6H)-one; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| US-20110059886-A1 | HCV NS3-NS4A Protease Inhibition | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| WO-2011022805-A1 | NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF | ALBERTA HEALTH SERVICES (CA) | 2011-03-03 | — | — | WO | disclosed |
| US-20110053911-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2011-03-03 | — | — | US | disclosed |
| EP-1737843-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7893081-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893082-B2 | Antitumor agents; anticancer agents | MERCK PATENT GMBH (DE) | 2011-02-22 | — | — | US | disclosed |
| US-7884199-B2 | computer aided drug design; pharmacogenetics around telaprevir resistance; hepatitis C virus (HCV) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-08 | — | — | US | disclosed |
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20110028472-A1 | THIENOPYRIMIDINES | MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-03 | — | — | US | disclosed |
| EP-2278969-A2 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE | 2011-01-27 | — | — | US | disclosed |
| EP-1856061-B1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | MERCK PATENT GMBH (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-7875614-B2 | compounds for treatment of tumors | MERCK PATENT GMBH (DE) | 2011-01-25 | — | — | US | disclosed |
| CN-101952255-A | Compounds for inhibiting KSP kinesin activity | SCHERING CORP | 2011-01-19 | — | — | CN | disclosed |
| US-7872024-B2 | Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions | MERCK SHARP & DOHME CORP. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7868172-B2 | 2-(hetero)-aryl substituted tetrahydroquinoline derivatives | MERCK PATENT GMBH (DE) | 2011-01-11 | — | — | US | disclosed |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2011-01-06 | — | — | US | disclosed |
| US-7863294-B2 | Heterocycle derivatives as histone deacetylase (HDAC) inhibitors | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-01-04 | — | — | US | disclosed |
| WO-2010149257-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | MERCK PATENT GMBH (DE) | 2010-12-29 | — | — | WO | disclosed |
| EP-2265590-A2 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265611-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265575-A2 | SULFONAMIDES | Merck Serono S.A. (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100324092-A1 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324074-A1 | Protein Kinase Inhibitors | ZHANG JUNHU | 2010-12-23 | — | — | US | disclosed |
| US-20100324063-A1 | JAK2 TYROSINE KINASE INHIBITION | VERTEX PHARMACEUTICALS INCORPORATED | 2010-12-23 | — | — | US | disclosed |
| WO-2010144909-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| CN-101918404-A | 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidine-2-amine derivatives | MERCK PATENT GMBH | 2010-12-15 | — | — | CN | disclosed |
| US-7846927-B2 | N,N′-diphenylurea derivatives suitable as kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| CN-101903395-A | Compounds for inhibiting KSP kinesin activity | SCHERING CORP | 2010-12-01 | — | — | CN | disclosed |
| CN-101903365-A | Spiro-condensed 1,3, 4-thiadiazole derivatives for inhibiting KSP kinesin activity | SCHERING CORP | 2010-12-01 | — | — | CN | disclosed |
| CN-101903343-A | Be used to suppress the active compound of KSP kinesin | SCHERING CORP | 2010-12-01 | — | — | CN | disclosed |
| US-20100291034-A1 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292262-A1 | 4 (PYRROLO[2,3-C]PYRIDINE-3-YL)PYRIMIDIN-2-AMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | disclosed |
| WO-2010132520-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | SCHERING CORPORATION (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2249854-A1 | IMPROVED TREATMENT AND PROPHYLAXIS | Mater Medical Research Institute (AU) | 2010-11-17 | — | — | EP | disclosed |
| US-7834015-B2 | treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV skin damage, and as chemosensitizers or radiosensitizers for cancer treatment | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-11-16 | — | — | US | disclosed |
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834026-B2 | histone deacetylase inhibitors; antiproliferative; antineoplastic; thioredoxin (TRX)-mediated diseases such as autoimmune, allergy, inflammatory diseases; and neurodegenerative diseases; N-(2-Aminophenyl)-6-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)nicotinamide; hydroxamic acid moiety | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834054-B2 | Use of the histone deacetylase inhibitor N-hydroxy-4-[2-(3-dimethylaminobenzofuran-2-ylcarbonylamino)ethoxy]benzamide (aka CRA-24781, PCI-24781) for treating myelogenous leukemia (MML) or acute myelogenous leukemia (AML), optionally in combination therapy | PHARMACYCLICS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| EP-2247185-A2 | TYROSINE KINASE INHIBITORS | Tiger Pharmatech (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100280006-A1 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2010-11-04 | — | — | US | disclosed |
| CN-1980938-B | Mitotic kinesin inhibitors | MERCK & CO INC | 2010-11-03 | — | — | CN | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100267709-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267801-A1 | CYCLOHEXYL SULPHONES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| EP-2240466-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | Merck Sharp & Dohme Limited (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-7816365-B2 | Amine derivatives | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| WO-2010115491-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA S.R.L. (IT) | 2010-10-14 | — | — | US | disclosed |
| CN-1953768-B | Highly concentrated liquid formulations of anti-EGFR antibodies | MERCK PATENT GMBH | 2010-10-13 | — | — | CN | disclosed |
| WO-2010114780-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| WO-2010112124-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-07 | — | — | WO | disclosed |
| EP-1878720-B1 | Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | disclosed |
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231143-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | disclosed |
| EP-1765830-B1 | MITOTIC KINESIN INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7799825-B2 | Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-09-21 | — | — | US | disclosed |
| US-20100234374-A1 | Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-09-16 | — | — | US | disclosed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234394-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2010104705-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-09-16 | — | — | WO | disclosed |
| US-7795304-B2 | such as S)-[6-Hydroxycarbamoyl-1-(4-phenyl-thiazol-2-ylcarbamoyl)-hexyl]-carbamic acid benzyl ester, useful in the prevention and/or treatment cancer, restenosis, autoimmune diseases, allergies, inflammatory diseases, nervous system disorders such as neurodegenerative diseases | MERCK SHARP & DOHME CORP. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795290-B2 | 2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| CN-101827851-A | 5-cyano-thienopyridines for the treatment of tumors | MERCK PATENT GMBH | 2010-09-08 | — | — | CN | disclosed |
| US-7790739-B2 | receptor tyrosine kinase MET inhibitors; anticancer agents; 8-phenyl-10H-furo[2',3':4,5]cyclohepta[1,2-b]pyridin-10-one | Merck & Co., Inc. and Merck Sharp & Dohme Corp. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100222321-A1 | Inhibitors of akt activtiy | MERCK SHARP & DOHME LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | disclosed |
| CN-101810592-A | Contain the pharmaceutical preparation that is dispersed in the active matter in the substrate | ALTANA PHARMA AG | 2010-08-25 | — | — | CN | disclosed |
| CN-101815714-A | Thiazol derivatives | MERCK PATENT GMBH | 2010-08-25 | — | — | CN | disclosed |
| EP-2220061-A1 | SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY | Schering Corporation (US) | 2010-08-25 | — | — | EP | disclosed |
| EP-2220073-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-08-25 | — | — | EP | disclosed |
| US-7781475-B2 | Oxindoles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20100209418-A1 | Solid Forms of a Raf Kinase Inhibitor | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| US-20100210623-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-08-19 | — | — | US | disclosed |
| CN-101809001-A | Imdazole derivatives | MERCK PATENT GMBH | 2010-08-18 | — | — | CN | disclosed |
| EP-2217605-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | Schering Corporation (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2217568-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | Schering Corporation (US) | 2010-08-18 | — | — | EP | disclosed |
| CN-101808988-A | Piperidine and piperazine derivatives | MERCK PATENT GMBH | 2010-08-18 | — | — | CN | disclosed |
| CN-101801379-A | CSF-1R inhibitors for treatment of cancer and bone diseases | NOVARTIS AG | 2010-08-11 | — | — | CN | disclosed |
| EP-2215064-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | Schering Corporation (US) | 2010-08-11 | — | — | EP | disclosed |
| US-7772265-B2 | 2-oxadiazolechromone derivatives | MERCK PATENT GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772238-B2 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197757-A1 | OXINDOLES AS KINASE INHIBITORS | BURGDORF LARS THORE | 2010-08-05 | — | — | US | disclosed |
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
| EP-2211862-A2 | CSF-1R INHIBITORS FOR TREATMENT OF CANCER AND BONE DISEASES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| EP-2211620-A1 | THERAPEUTIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2010-08-04 | — | — | EP | disclosed |
| US-7767696-B2 | Antitumor agents; tyrosine inhbitor; controllling kinase signal transduction | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7763634-B2 | Inhibitors of janus kinases | MERCK & CO., INC. (US) | 2010-07-27 | — | — | US | disclosed |
| WO-2010078897-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| EP-2205070-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20100173923-A1 | 4 (PYRROLOPYRIDINYL)PYRIMIDINYL-2-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173895-A1 | IMIDAZOLOPYRIMIDINES AND IMIDAZOLOTRIAZINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2010-07-08 | — | — | US | disclosed |
| US-7750151-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010072295-A1 | NOVEL POLYMORPHIC FORMS OF 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-{3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2010-07-01 | — | — | WO | disclosed |
| EP-1891008-B1 | OXINDOLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2010-06-30 | — | — | EP | disclosed |
| EP-2200612-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7745639-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745434-B2 | 4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours | MERCK PATENT GMBH (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20100160327-A1 | Modified Malonate Derivatives | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160309-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160356-A1 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-06-24 | — | — | US | disclosed |
| CN-101754965-A | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG | 2010-06-23 | — | — | CN | disclosed |
| US-20100152180-A1 | 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-06-17 | — | — | US | disclosed |
| CN-1894276-B | HCV NS3-NS4A protease resistance mutants | VERTEX PHARMA | 2010-06-16 | — | — | CN | disclosed |
| US-7737184-B2 | Histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| WO-2010063352-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | MERCK PATENT GMBH (DE) | 2010-06-10 | — | — | WO | disclosed |
| EP-2193121-A1 | QUINOLIN-4-ONE AND 4-OXODIHYDROCINNOLINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-06-09 | — | — | EP | disclosed |
| US-7732465-B2 | Substituted benzimidazoles and methods of their use | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732472-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-7723365-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2185554-A1 | SILICON DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7718687-B2 | Dihydropyrrole derivatives; 3-{(2S)-4-(2,5-difluorophenyl)-1-[(dimethylamino)carbonyl]-2,5-dihydro- 1H-pyrrol-2-yl}phenyl dihydrogen phosphate; anticarcinogenic agents; cellular proliferative diseases; specificity; side effect reduction | MERCK SHARP & DOHME CORP., (US) | 2010-05-18 | — | — | US | disclosed |
| US-20100120818-A1 | SUBSTITUTED TETRAHYDROPYRROLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
| US-7705138-B2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705014-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2010-04-27 | — | — | US | disclosed |
| CN-101696232-A | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2010-04-21 | — | — | CN | disclosed |
| US-7700601-B2 | Substituted indazoles of formula 1.0 that are kinase inhibitors | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| CN-101693672-A | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2010-04-14 | — | — | CN | disclosed |
| US-7696224-B2 | Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| EP-2170339-A2 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| CN-101687838-A | Pyrrolo [3, 2-A ] pyridine derivatives that inhibit KSP kinesin activity | SCHERING CORP | 2010-03-31 | — | — | CN | disclosed |
| EP-2168578-A2 | 2-Amido-Thiazole-Based Compounds Exhibiting ATP-Utilizing Enzyme Inhibitory Activity, and Compositions, and Uses Thereof | Genentech, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100075970-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
| US-20100076012-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| CN-101679372-A | Solid forms of a RAF kinase inhibitor | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| CN-101679266-A | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| CN-101679425-A | 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives | MERCK PATENT GMBH | 2010-03-24 | — | — | CN | disclosed |
| US-20100068181-A1 | PYRROLO [3, 2-A] PYRIDINE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION | 2010-03-18 | — | — | US | disclosed |
| EP-1620411-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2010-03-17 | — | — | EP | disclosed |
| CN-101674820-A | The method of using histone deacetylase inhibitors and monitoring biomarkers in therapeutic alliance | PHARMACYCLICS INC | 2010-03-17 | — | — | CN | disclosed |
| US-20100063028-A1 | Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| US-7666862-B2 | 2,4-Diphenyl-1-(hexamethylenimin-4-ylaminocarbonyl)dihydropyrrole derivatives that are useful for treating cancer | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| EP-2152700-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | Novartis Ag (CH) | 2010-02-17 | — | — | EP | disclosed |
| US-7662827-B2 | Pyrazole derivatives having tyrosine kinase inhibitory activity | MERCK PATENT GMBH (DE) | 2010-02-16 | — | — | US | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010012345-A1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014453-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| CN-101641362-A | Substituted tetrahydroquinolines | MERCK PATENT GMBH DE | 2010-02-03 | — | — | CN | disclosed |
| US-7655695-B2 | Illudin analogs useful as anticancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655649-B2 | Cancer; N,N-dimethyl-5-phenyl-6-(4-{[4-(5-pyridin-2-yl-1H-pyrazol-3-yl)piperidin-1-yl]methyl}phenyl) pyridazin-3-amine;; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, enhanced pharmacokinetic properties | MERCK SHARP & DOHME CORP. (US) | 2010-02-02 | — | — | US | disclosed |
| WO-2010011375-A2 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022530-A1 | TETRAHYDROBENZOISOXAZOLE AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN | MERCK PATENT GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022579-A1 | SUBSTITUTED TETRAHYDROQUINOLINES | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022573-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2010-01-28 | — | — | US | disclosed |
| US-20100022630-A1 | Method of treatment using fatty acid synthesis inhibitors | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| CN-101636401-A | Tetrahydroquinoline derivatives and their use for the treatment of cancer | MERCK PATENT GMBH | 2010-01-27 | — | — | CN | disclosed |
| CN-101633636-A | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2010-01-27 | — | — | CN | disclosed |
| WO-2010006438-A1 | THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | WO | disclosed |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| WO-2010005841-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20100004253-A1 | BIOMARKERS OF TARGET MODULATION, EFFICACY, DIAGNOSIS AND/OR PROGNOSIS FOR RAF INHIBITORS | NOVARTIS AG | 2010-01-07 | — | — | US | disclosed |
| WO-2010002955-A2 | STEMNESS SIGNATURE BIOMARKERS AND METHODS OF USE | MERCK & CO., INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| CN-101616918-A | 4- (pyrrolopyridinyl) pyrimidin-2-ylamine derivatives | MERCK PATENT GMBH | 2009-12-30 | — | — | CN | disclosed |
| US-7638549-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropyrrolidin3-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide; antiproliferative and -carcinogenic agents | MERCK & CO. INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638530-B2 | 1-{1-[4-(3-amino-5-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; anticarcinogenic agents | MERCK & CO., INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090318444-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | MERCK PATENT GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318541-A1 | Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions | MERCK SHARP & DOHME LLC | 2009-12-24 | — | — | US | disclosed |
| EP-2134346-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | Merck & Co., Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009155156-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-2132198-A1 | SOLID FORMS OF A RAF KINASE INHIBITOR | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| US-7632833-B2 | Anticancer agents | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632839-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090306122-A1 | SUBSTITUTED TETRAHYDROPYRROLOQUINOLINE DERIVATIVES AS KINASE MODULATORS, ESPECIALLY OF TYROSINE AND RAF KINASES | MERCK PATENT GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306058-A1 | Sulphone Derivatives for Treatment of Cancer | MERCK SHARP & DOHME LTD. (GB) | 2009-12-10 | — | — | US | disclosed |
| WO-2009148916-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009148887-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090306071-A1 | Inhibitors of Janus Kinases | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | disclosed |
| EP-1871765-B1 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2009-12-09 | — | — | EP | disclosed |
| CN-100567289-C | 2- (hetero) aryl-substituted tetrahydroquinoline derivatives | MERCK PATENT GMBH (DE) | 2009-12-09 | — | — | CN | disclosed |
| US-7629373-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629347-B2 | Protein tyrosine kinase inhibitors | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2009-12-08 | — | — | US | disclosed |
| US-20090298855-A1 | Protein Tyrosine Kinase Inhibitors | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2009-12-03 | — | — | US | disclosed |
| US-7625936-B2 | 3,5-Diphenyl-4,5-dihydro-1H-dipyrazole derivatives such as {2-[1-acetyl-3-(2,5-difluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-5-yl]ethyl}(dimethyl)silanol that are useful for treating cancer | MERCK & CO. INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625912-B2 | 2-Phenylpyrimidinone compounds; anticarcinogenic agents can be synergistically combined with one or more active ingredients such as paclitaxel or trastuzumab; side effect reduction | MERCK & CO. INC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090291965-A1 | Histone Deacetylase Inhibitors With Aryl-Pyrazolyl-Motifs | MERCK SHARP & DOHME LLC | 2009-11-26 | — | — | US | disclosed |
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-11-26 | — | — | US | disclosed |
| EP-2120951-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121681-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | Critical Outcome Technologies, Inc. (CA) | 2009-11-25 | — | — | EP | disclosed |
| US-7622489-B2 | Kinesin spindle protein inhibitor; antiproliferative agents; anticancer agents; 4-(2,5-difluorophenyl)-N-3-fluoropyrrolidin-3-yl)-2-hydroxymethyl-2-phenyl-2,5-dihydro-1N-pyrrol-1-carboxamide | MERCK & CO., INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622468-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7618971-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1492487-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-11-05 | — | — | US | disclosed |
| EP-1481077-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7612093-B2 | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy | UNITED THERAPEUTICS CORPORATION (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| EP-1631548-B1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-10-28 | — | — | EP | disclosed |
| US-7608739-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608643-B2 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| WO-2009129335-A2 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| EP-2109607-A1 | PYRROLO[3, 2-A]PYRIDINE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-2109608-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-10-21 | — | — | EP | disclosed |
| EP-1515724-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2009124962-A2 | SULFONAMIDES | MERCK SERONO S.A. (CH) | 2009-10-15 | — | — | WO | disclosed |
| CN-100548296-C | The mitotic kinesins inhibitor | MERCK & CO INC (US) | 2009-10-14 | — | — | CN | disclosed |
| CN-100549006-C | The mitotic kinesins inhibitor | MERCK & CO INC (US) | 2009-10-14 | — | — | CN | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-7598274-B2 | N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors | MERCK PATENT GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20090247565-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | disclosed |
| EP-2104669-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2009-09-30 | — | — | EP | disclosed |
| US-7595337-B2 | 2-Carbonyl-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole derivatives such as 2-acetyl-8-fluoro-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole and 3S,3aS)-2-acetyl-8-chloro-7-methyl-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole that are useful for treating cancer | MERCK & CO. INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| EP-2102212-A1 | IMIDAZOLOPYRIMIDINES AND IMIDAZOLOTRIAZINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-09-23 | — | — | EP | disclosed |
| CN-101541977-A | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for RAF inhibitors | NOVARTIS AG (CH) | 2009-09-23 | — | — | CN | disclosed |
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| WO-2009112832-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-09-17 | — | — | WO | disclosed |
| EP-2099442-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2009-09-16 | — | — | EP | disclosed |
| CN-101535268-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2009-09-16 | — | — | CN | disclosed |
| US-7589068-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-09-15 | — | — | US | disclosed |
| WO-2009111354-A2 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227598-A1 | Ret Tyrosine Kinase Inhibition | MERCK SHARP & DOHME CORP. | 2009-09-10 | — | — | US | disclosed |
| US-7585866-B2 | Modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; cancer; chronic myelogic leukemia | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2009-09-08 | — | — | US | disclosed |
| US-20090221669-A1 | Disubstituted Aniline Compounds | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090220454-A1 | Use of the histone deacetylase inhibitor N-hydroxy-4-[2-(3-dimethylaminobenzofuran-2-ylcarbonylamino)ethoxy]benzamide (aka CRA-24781, PCI-24781) for treating myelogenous leukemia (MML) or acute myelogenous leukemia (AML), optionally in combination therapy | PHARMACYCLICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| CN-101522675-A | 2-amido-4-isoxazolyl thiazole compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH INC (US) | 2009-09-02 | — | — | CN | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090215775-A1 | Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer | MERCK SHARP & DOHME LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE | 2009-08-27 | — | — | US | disclosed |
| CN-101516389-A | Combination therapy for the treatment of viral infections | UNITED THERAPEUTICS CORP (US) | 2009-08-26 | — | — | CN | disclosed |
| US-7579355-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090209523-A1 | Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-08-20 | — | — | US | disclosed |
| US-20090209566-A1 | Spirocyclic Compounds | MERCK SHARP & DOHME LLC | 2009-08-20 | — | — | US | disclosed |
| WO-2009102537-A1 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| US-7576209-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090203684-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| EP-1874295-A4 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MERCK SHARP & DOHME LLC | 2009-08-06 | — | — | US | disclosed |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| EP-2083831-A2 | METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| CN-101500613-A | A novel lactic acid formulation of MK-0457 useful for the treatment of cancer | MERCK & CO INC (US) | 2009-08-05 | — | — | CN | disclosed |
| CN-100522991-C | Peptidomimetic protease inhibitors | LILLY CO ELI (US) | 2009-08-05 | — | — | CN | disclosed |
| CN-101501006-A | Pyridone and pyridazinone derivatives as poly (ADP-ribose) polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-08-05 | — | — | CN | disclosed |
| US-20090191555-A1 | HCV NS3-NS4 Protease Resistance Mutants | VERTEX PHARMACEUTICALS (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| EP-1784175-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1773326-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090182001-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-07-16 | — | — | US | disclosed |
| US-20090182002-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-07-16 | — | — | US | disclosed |
| WO-2009087381-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LTD (GB) | 2009-07-16 | — | — | WO | disclosed |
| EP-1804821-A4 | HCV NS3-NS4A PROTEASE INHIBITION | VERTEX PHARMA (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1910365-A4 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1458726-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090176765-A1 | Pyridinone and Pyridazinone Derivatives as Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) | MSD ITALIA S.R.L. (IT) | 2009-07-09 | — | — | US | disclosed |
| US-20090170904-A1 | Substituted benzimidazoles and methods of their use | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| EP-2074226-A2 | BIOMARKERS OF TARGET MODULATION, EFFICACY, DIAGNOSIS AND/OR PROGNOSIS FOR RAF INHIBITORS | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-7553854-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553838-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1954698-B1 | SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS | MERCK & CO INC (US) | 2009-06-24 | — | — | EP | disclosed |
| US-7550478-B2 | Tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550477-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550470-B2 | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| WO-2009073911-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156619-A1 | Heterocycle Substituted Amide and Sulfur Amide Derivatives as Histone Deacetylase (HDAC) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-06-18 | — | — | US | disclosed |
| US-20090156591-A1 | Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-06-18 | — | — | US | disclosed |
| WO-2009075830-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156617-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
| WO-2009073916-A1 | IMPROVED TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2009-06-18 | — | — | WO | disclosed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7547695-B2 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1781286-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-06-10 | — | — | EP | disclosed |
| CN-101454314-A | Kinase inhibitors | SCHERING CORP (US) | 2009-06-10 | — | — | CN | disclosed |
| US-7544695-B2 | Spirocyclic compounds | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544677-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1773815-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7538231-B2 | Tyrosine kinase inhibitors | MERCK & CO, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| WO-2009063244-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-05-22 | — | — | WO | disclosed |
| US-20090130193-A1 | Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intraperitoneally | TRANSAVE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090130194-A1 | Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously | TRANSAVE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131506-A1 | Oxindoles as Kinase Inhibitors | MERCK PATENT GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7534918-B2 | Histone deacetylase inhibitors | MERCK & CO., INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| WO-2009061597-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090124641-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| WO-2009061596-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061595-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-1320540-B1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMA (US) | 2009-05-13 | — | — | EP | disclosed |
| CN-101432281-A | 6-O-substituted benzoxazole and benzothiazole compounds and methods for inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2009-05-13 | — | — | CN | disclosed |
| EP-2057157-A2 | 2-AMIDO-4-ISOXAZOLYL THIAZOLE COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | Genentech, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-2057161-A2 | 4-OXO-4,5-DIHYDROPYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-05-13 | — | — | EP | disclosed |
| US-20090118267-A1 | INDANES | MERCK PATENT GMBH (DE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118291-A1 | Histone deacetylase inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528139-B2 | Antitumor agents; N-[4-(4-amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)phenyl]-2,3-dichlorobenzenesulfonamide; inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases; sulfonamidation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2009-05-05 | — | — | US | disclosed |
| WO-2009054941-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-7524850-B2 | 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; serine/threonine protein kinase; antiproliferative | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | MERCK SHARP & DOHME CORP. | 2009-04-23 | — | — | US | disclosed |
| US-20090105270-A1 | Kinase inhibition and anticancer therapy | BUSER-DOEPNER CAROLYN A | 2009-04-23 | — | — | US | disclosed |
| WO-2009052288-A1 | SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050228-A2 | CSF-1R INHIBITORS FOR TREATMENT OF CANCER AND BONE DISEASES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| EP-2049124-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| CN-101415686-A | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-04-22 | — | — | CN | disclosed |
| EP-2049494-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1656146-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-7517988-B2 | N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethylsulfonyl]-benzamide; hepatitis C; inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| WO-2009045385-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| CN-101405295-A | Hepatitis C virus variants | VERTEX PHARMA (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-2040546-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1620095-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| EP-1635641-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7507858-B2 | Histone deacetylase inhibitors | MERCK & CO., INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090076101-A1 | Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-03-19 | — | — | US | disclosed |
| WO-2009035575-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-1581497-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7504429-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090069391-A1 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| EP-2032140-A1 | PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-03-11 | — | — | EP | disclosed |
| EP-1697381-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-2032141-A1 | INHIBITORS OF JANUS KINASES | Merck & Co., Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| WO-2009027730-A1 | QUINOLIN-4-ONE AND 4-OXODIHYDROCINNOLINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062297-A1 | Hydroxyalkylarylamide Derivatives | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062327-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062302-A1 | Jak2 Tyrosine Kinase Inhibition | VERTEX PHARMACEUTICALS INCORPORATED | 2009-03-05 | — | — | US | disclosed |
| EP-1656140-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1651209-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1551812-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090054448-A1 | Amino Acid Derivatives as Histone Deacetylase (HDAC) Inhibitors | JONES PHILIP | 2009-02-26 | — | — | US | disclosed |
| CN-101374515-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2009-02-25 | — | — | CN | disclosed |
| US-7494660-B2 | HCV NS3-NS4A protease resistance mutants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | GENENTECH, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
| EP-2023924-A2 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | Merck & Co., Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2009020589-A1 | SILICON DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042966-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| CN-100457728-C | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2009-02-04 | — | — | CN | disclosed |
| US-7485649-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20090030028-A1 | Tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1737843-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-01-28 | — | — | EP | disclosed |
| US-7482367-B2 | Substituted benzimidazoles and methods of their use | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482466-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090023767-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-01-22 | — | — | US | disclosed |
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1664026-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | disclosed |
| CN-101346383-A | Triazole derivatives | MERCK PATENT GMBH (DE) | 2009-01-14 | — | — | CN | disclosed |
| EP-2013196-A2 | DISUBSTITUTED ANILINE COMPOUNDS | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-2013212-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2009005638-A2 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | disclosed |
| US-20090012061-A1 | A Method of Treating Cancer | MERCK SHARP & DOHME CORP. | 2009-01-08 | — | — | US | disclosed |
| US-20090012075-A1 | Fluorinated Arylamide Derivatives | MERCK SHARP & DOHME CORP. | 2009-01-08 | — | — | US | disclosed |
| EP-2010528-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | Novartis Pharma AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| CN-101341151-A | Diazepinones | MERCK PATENT GMBH (DE) | 2009-01-07 | — | — | CN | disclosed |
| US-20090005418-A1 | Mitotic Kinesin Inhibitors | MERCK & CO., INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| EP-2007733-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2008-12-31 | — | — | EP | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20080318934-A1 | Diazepinoes | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-2004631-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | Merck Patent GmbH (DE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008153701-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312278-A1 | Hydroxyquinoline Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-18 | — | — | US | disclosed |
| EP-2001870-A2 | KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-17 | — | — | EP | disclosed |
| US-7465746-B2 | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP | MERCK & CO., INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306147-A1 | Illudin Analogs Useful as Anticancer Agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1998759-A2 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1868601-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2008144062-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2008-11-27 | — | — | WO | disclosed |
| CN-101312976-A | Spirocyclic compounds as hdac inhibitors | MERCK & CO INC (US) | 2008-11-26 | — | — | CN | disclosed |
| US-20080287457-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
| WO-2008140850-A1 | SOLID FORMS OF A RAF KINASE INHIBITOR | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| EP-1991226-A2 | INHIBITORS OF HISTONE DEACETYLASE | Merck & Co., Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20080280899-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080280889-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-20080267915-A1 | Hcv Ns3-Ns4a Protease Inhibition | VERTEX PHARMACEUTICALS (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1656133-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080262035-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | MERCK & CO., INC. | 2008-10-23 | — | — | US | disclosed |
| EP-1981524-A2 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV POLYMERASE INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1981341-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | Merck and Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080255221-A1 | N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethylsulfonyl]-benzamide; hepatitis C; inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255214-A1 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1978958-A2 | RET TYROSINE KINASE INHIBITION | Merck & Co., Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1978964-A2 | JAK2 TYROSINE KINASE INHIBITION | Merck & Co., Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1976523-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1976511-A2 | FLUORINATED ARYLAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080242709-A1 | 2-AMIDO-4-ISOXAZOLYL THIAZOLE COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| EP-1973405-A2 | HYDROXYALKYLARYLAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| CN-100422158-C | Inhibitors of Akt activity | MERCK & CO INC (US) | 2008-10-01 | — | — | CN | disclosed |
| CN-100421665-C | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-10-01 | — | — | CN | disclosed |
| US-20080234299-A1 | Quinazolinones | MERCK PATENT GMBH (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-25 | — | — | US | disclosed |
| EP-1651599-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7427637-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2008-09-23 | — | — | US | disclosed |
| WO-2008112217-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE (IT) | 2008-09-11 | — | — | US | disclosed |
| US-20080221118-A1 | treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle | MERCK PATENT GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| CN-101263125-A | Quinazoline derivatives useful in cancer treatment | SCHERING CORP (US) | 2008-09-10 | — | — | CN | disclosed |
| CN-101263124-A | Quinazoline derivatives useful in cancer treatment | SCHERING CORP (US) | 2008-09-10 | — | — | CN | disclosed |
| US-20080214582-A1 | Purine Derivatives as Inhibitors of Receptor Tyrosine Kinase Activity | MERCK PATENT GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080214594-A1 | Inhibitors Of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-09-04 | — | — | US | disclosed |
| CN-101257924-A | Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents | WARNER LAMBERT CO (US) | 2008-09-03 | — | — | CN | disclosed |
| EP-1636182-A4 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7420089-B2 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080207682-A1 | Phenylurea Derivatives As Inhibitors Of Tyrosine Kinases For The Treatment Of Tumour Diseases | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207699-A1 | Pyrazole Derivatives | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207693-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| US-20080207647-A1 | Pyrazole Derivatives Having Tyrosine Kinase Activity | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| CN-101253168-A | Substituted benzimidazoles as kinase inhibitors | NOVARTIS AG (CH) | 2008-08-27 | — | — | CN | disclosed |
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | MERCK PATENT GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080199459-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-08-21 | — | — | US | disclosed |
| EP-1958956-A2 | Peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7414055-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080194569-A1 | Phthalazinones | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194582-A1 | 3,5-Diphenyl-4,5-dihydro-1H-dipyrazole derivatives such as {2-[1-acetyl-3-(2,5-difluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-5-yl]ethyl}(dimethyl)silanol that are useful for treating cancer | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| US-20080194615-A1 | Antitumor agents; anticancer agents | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194605-A1 | (1H-Ind0l-7-Yl)-(Pyrimidin-2-Ylamino)Methanone Derivatives and Related Compounds as Igf-R1 Inhibitors for the Treatment of Cancer | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1954290-A2 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| CN-101242834-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2008-08-13 | — | — | CN | disclosed |
| EP-1954698-A1 | SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7410988-B2 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1951748-A2 | HEPATITIS C VIRUS VARIANTS | Vertex Pharmaceuticals, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1951252-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1951047-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1951249-A2 | TYROSINE KINASE INHIBITORS | Merck and Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080182879-A1 | 2-OXADIAZOLECHROMONE DERIVATIVES | MUJICA-FERNAUD TERESA | 2008-07-31 | — | — | US | disclosed |
| US-20080182843-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-07-31 | — | — | US | disclosed |
| WO-2008090379-A1 | PYRAZOLOQUINAZOLINONES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-07-31 | — | — | WO | disclosed |
| EP-1658846-B1 | N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol for treating hepatitis virus infections | UNITED THERAPEUTICS CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080176892-A1 | Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1945028-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | Merck & Co., Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008084261-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008083491-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2008-07-17 | — | — | WO | disclosed |
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | 6441513 CANADA INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-7399764-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2008-07-15 | — | — | US | disclosed |
| WO-2008082856-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008082730-A2 | BIOMARKERS OF TARGET MODULATION, EFFICACY, DIAGNOSIS AND/OR PROGNOSIS FOR RAF INHIBITORS | NOVARTIS AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| CN-101217958-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2008-07-09 | — | — | CN | disclosed |
| US-7396832-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080161317-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
| WO-2008079293-A1 | PYRROLO [3, 2-A] PYRIDINE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1791969-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080153887-A1 | Mitotic Kinesin Inhibitors | MERCK & CO., INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153877-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| EP-1934200-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080146560-A1 | 4-Amino-5-Oxo-8-Phenyl-5H-Pyrido(2,3-D) Pyrimidine Derivatives as Tyrosine Kinase and Raf Kinase Inhibitors for the Treatment of Tumours | MERCK PATENT GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146589-A1 | Tyrosine kinase inhibitors; antitumor agents; food supplements; for treating non-hyperproliferative diseases; signal transduction; oxidative stress; neurodegenerative diseases | MUJICA-FERNAUD TERESA | 2008-06-19 | — | — | US | disclosed |
| CN-101203495-A | Benzocycloheptapyridine compounds as inhibitors of receptor tyrosine kinase MET | MERCK & CO INC (US) | 2008-06-18 | — | — | CN | disclosed |
| US-20080139586-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | disclosed |
| WO-2008070016-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139547-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070134-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| CN-101198613-A | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2008-06-11 | — | — | CN | disclosed |
| EP-1534695-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080131398-A1 | Glucosidase inhibitors; interferons; antifibrotics; hepatitis | UNITED THERAPEUTICS CORPORATION | 2008-06-05 | — | — | US | disclosed |
| EP-1926722-A1 | SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS | Novartis AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| CN-101193637-A | Fluorinated aminoalkyl-4-oxo-3, 4-dihydropyrido [3, 4-d ] pyrimidine compounds as mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-06-04 | — | — | CN | disclosed |
| EP-1558609-A4 | KINASE INHIBITORS | MERCK & CO INC (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1496898-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1924289-A2 | FORMULATION AND METHOD FOR ENHANCEMENT OF GASTROINTESTINAL ABSORPTION OF PHARMACEUTICAL AGENTS | Warner-Lambert Company LLC (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1924568-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7378421-B2 | Chromenone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-05-27 | — | — | US | disclosed |
| US-7378411-B2 | Substituted thienopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2008056187-A1 | IMIDAZOLOPYRIMIDINES AND IMIDAZOLOTRIAZINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-05-15 | — | — | WO | disclosed |
| US-20080114026-A1 | N,N'-Diphenylurea Derivatives Which are Suitable as Kinase Inhibitors | MERCK PATENT GMBH (DE) | 2008-05-15 | — | — | US | disclosed |
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| US-7371754-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7368476-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368572-B2 | Acetylene derivatives as inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080102068-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-05-01 | — | — | US | disclosed |
| CN-101171254-A | Fused thieno[2,3-B]pyridine and thiazolo[5,4-B]pyridine compounds for inhibiting KSP kinesin activity | SCHERING CORP (US) | 2008-04-30 | — | — | CN | disclosed |
| EP-1915351-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-04-30 | — | — | EP | disclosed |
| CN-101171052-A | Compounds that inhibit KSP kinesin activity | SCHERING CORP (US) | 2008-04-30 | — | — | CN | disclosed |
| US-20080096920-A1 | Histone Deacetylase Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-24 | — | — | US | disclosed |
| CN-100382804-C | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections | SEARLE & CO (US) | 2008-04-23 | — | — | CN | disclosed |
| CN-101163690-A | Benzothiophene hydroxamic acid derivatives | MERCK & CO INC (US) | 2008-04-16 | — | — | CN | disclosed |
| CN-101163471-A | Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions | MERCK & CO INC (US) | 2008-04-16 | — | — | CN | disclosed |
| EP-1909783-A2 | ILLUDIN ANALOGS USEFUL AS ANTICANCER AGENTS | The Regents of the University of California (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910365-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008041037-A1 | FUSED INDOLES AND INDAZOLES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-04-10 | — | — | WO | disclosed |
| US-7354945-B2 | 2-oxadiazolechromone derivatives | MERCK PATENT GMBH (DE) | 2008-04-08 | — | — | US | disclosed |
| WO-2008039327-A2 | METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1904449-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| CN-101155588-A | Inhibitors of akt activity | MERCK & CO INC (US) | 2008-04-02 | — | — | CN | disclosed |
| US-7348431-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348440-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1898903-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1898941-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2008-03-19 | — | — | EP | disclosed |
| CN-101146796-A | 3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer | SCHERING CORP (US) | 2008-03-19 | — | — | CN | disclosed |
| CN-101142183-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-03-12 | — | — | CN | disclosed |
| EP-1896422-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896421-A2 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | Merck & Co., Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1730099-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896395-A2 | MODIFIED MALONATE DERIVATIVES | Merck & Co., Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| CN-101137372-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-03-05 | — | — | CN | disclosed |
| EP-1893607-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1891089-A2 | HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD | SCHERING CORPORATION (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1781287-A4 | THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENYZMES | GENENTECH INC (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1891008-A1 | OXINDOLES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2008-02-27 | — | — | EP | disclosed |
| CN-101133024-A | Amide derivatives as histone deacetylase inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2008-02-27 | — | — | CN | disclosed |
| WO-2008022002-A2 | 2-AMIDO-4-ISOXAZOLYL THIAZOLE COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | GENENTECH, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG | 2008-02-21 | — | — | US | disclosed |
| US-20080045492-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-02-21 | — | — | US | disclosed |
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1888050-A2 | CYCLOHEXYL SULPHONES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008017883-A2 | 4-OXO-4,5-DIHYDROPYRROLO[1,2-A] QUINOXALINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-02-14 | — | — | WO | disclosed |
| US-7329762-B2 | Prodrugs of mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20080032980-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-02-07 | — | — | US | disclosed |
| US-20080033015-A1 | Histone Deacetylase Inhibitors | MERCK SHARP & DOHME LLC | 2008-02-07 | — | — | US | disclosed |
| EP-1765334-A4 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20080027118-A1 | Prodrugs Of Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| US-20080027058-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| CN-100364534-C | Use of n-substituted-1,5-di deoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | SEARLE & CO (US) | 2008-01-30 | — | — | CN | disclosed |
| CN-101115479-A | Inhibitors of akt activity | MERCK & CO INC (US) | 2008-01-30 | — | — | CN | disclosed |
| CN-101115742-A | Heterocycle derivatives as histone deacetylase (hdac) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2008-01-30 | — | — | CN | disclosed |
| CN-101115724-A | Inhibitors of checkpoint kinases | MERCK & CO INC (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1881986-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-01-30 | — | — | EP | disclosed |
| CN-101115745-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-01-30 | — | — | CN | disclosed |
| US-20080021019-A1 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds | SCHERING CORPORATION | 2008-01-24 | — | — | US | disclosed |
| WO-2008010985-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080015190-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME CORP. | 2008-01-17 | — | — | US | disclosed |
| WO-2008008310-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015212-A1 | Inhibitors Of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-01-17 | — | — | US | disclosed |
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015216-A1 | Histone Deacetylase Inhibitors | MERCK SHARP & DOHME LLC | 2008-01-17 | — | — | US | disclosed |
| CN-101106998-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-01-16 | — | — | CN | disclosed |
| CN-101107220-A | Amide derivatives as inhibitors of histone deacetylase | ANGELETTI P INST RICHERCHE BIO (IT) | 2008-01-16 | — | — | CN | disclosed |
| CN-101107253-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-01-16 | — | — | CN | disclosed |
| EP-1878720-A1 | Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| US-20080009507-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| EP-1876173-A1 | Chiral intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1874755-A2 | BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1874295-A1 | BENZOTHIOPHENE DERIVATIVES | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1874294-A1 | BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES WITH CARBAMATE, UREA, AMIDE AND SULFONAMIDE SUBSTITUTIONS | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | MERCK & CO., INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| WO-2008001134-A1 | 1,2,3,8,9,9A-HEXAHYDRO-7H-BENZO(DE)-1,7-NAPHTHYRIDIN-7-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-01-03 | — | — | WO | disclosed |
| EP-1871765-A2 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871776-A2 | FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871376-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007149427-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-1868601-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007144669-A1 | PYRAZOLO[1,5-A]QUINAZOLIN-5(4H)-ONES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145957-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293488-A1 | tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis | MERCK PATENT GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
| EP-1503757-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070287664-A1 | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto | SCHERING CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | disclosed |
| EP-1863571-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | Shering Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1551824-B1 | PROTEIN TYROSINE KINASE INHIBITORS | CRITICAL OUTCOME TECHNOLOGIES (CA) | 2007-12-12 | — | — | EP | disclosed |
| US-7307085-B2 | Kinesin spindle protein (KSP) inhibitors; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator; e.g. bicyclic dihydropyrrole derivatives | MERCK & CO., INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-7307100-B2 | compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction; cancer, tumour growth, arteriosclerosis, age-related macular degeneration, diabetic retinopathy, inflammatory diseases and the like | MERCK PATENT GMBH (DE) | 2007-12-11 | — | — | US | disclosed |
| WO-2007138355-A1 | PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139585-A1 | CONTROLLED-RELEASE FORMULATION | SCHERING CORPORATION (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| EP-1861097-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| CN-101084194-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2007-12-05 | — | — | CN | disclosed |
| EP-1861366-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7304063-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070274951-A1 | Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| WO-2007136605-A2 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-1784386-A4 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO INC (US) | 2007-11-28 | — | — | EP | disclosed |
| US-7301028-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1856061-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | Merck Patent GmbH (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1855685-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1855664-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1856128-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| CN-101076335-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2007-11-21 | — | — | CN | disclosed |
| CN-101072575-A | HCV NS 3-NS 4A protease inhibition | VERTEX PHARMA (US) | 2007-11-14 | — | — | CN | disclosed |
| US-7294640-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-11-13 | — | — | US | disclosed |
| WO-2007127137-A2 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127138-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007126964-A2 | KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1851213-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1851203-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1850843-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| CN-101068811-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2007-11-07 | — | — | CN | disclosed |
| US-20070254901-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| EP-1496896-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1696927-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1849797-A2 | Peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1631548-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007121484-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| EP-1620411-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244135-A1 | Sulfonamides | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| CN-101056620-A | Method of treating cancer by intraperitoneal administration of lipid-based platinum compound preparation | TRANSAVE INC (US) | 2007-10-17 | — | — | CN | disclosed |
| WO-2007113596-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007084135-A9 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO INC (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | SCHERING CORPORATION | 2007-10-11 | — | — | US | disclosed |
| US-20070231262-A1 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS, INCORPORATED | 2007-10-04 | — | — | US | disclosed |
| WO-2007111866-A2 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070232527-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| CN-101048158-A | Thiazole based inhibitors of ATP-utilizing enyzmes | GENENTECH INC (US) | 2007-10-03 | — | — | CN | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070225347-A1 | Imidazole Derivatives | MERCK PATENT GMBH (DE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007107594-A2 | SIX-MEMBERED HETEROCYCLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-09-27 | — | — | WO | disclosed |
| EP-1835918-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1836807-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7273869-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070219246-A1 | Dihydrobenzothiophenes | MERCK PATENT GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| CN-101039932-A | Heterocyclic substituted bisarylurea derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-09-19 | — | — | CN | disclosed |
| EP-1496907-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1831176-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| CN-101035542-A | Histone deacetylase inhibitors | MERCK & CO INC (US) | 2007-09-12 | — | — | CN | disclosed |
| WO-2007100657-A2 | INHIBITORS OF HISTONE DEACETYLASE | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-09-06 | — | — | US | disclosed |
| EP-1828171-A2 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-09-05 | — | — | EP | disclosed |
| EP-1463733-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1827436-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7265134-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070203167-A1 | 2-(Hetero)-aryl substituted tetrahydrochinoline | MERCK PATENT GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
| EP-1824849-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-7262186-B2 | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262199-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| WO-2007059221-A9 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMA (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070190180-A1 | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously | PILKIEWICZ FRANK G | 2007-08-16 | — | — | US | disclosed |
| WO-2007092616-A2 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV POLYMERASE INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070190182-A1 | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally | TRANSAVE, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070190181-A1 | Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously | PILKIEWICZ FRANK G | 2007-08-16 | — | — | US | disclosed |
| CN-101018547-A | Histone deacetylase inhibitors | MERCK & CO INC (US) | 2007-08-15 | — | — | CN | disclosed |
| WO-2007089634-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007087130-A2 | HYDROXYALKYLARYLAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087245-A2 | RET TYROSINE KINASE INHIBITION | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007064658-A9 | SAFE AND EFFECTIVE METHODS OF ADMINISTERING THERAPEUTIC AGENTS | TRANSAVE INC (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087246-A2 | JAK2 TYROSINE KINASE INHIBITION | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087129-A2 | FLUORINATED ARYLAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1811963-A2 | METHODS OF TREATING CANCER WITH LIPID-BASED PLATINUM COMPOUND FORMULATIONS ADMINISTERED INTRAPERITONEALLY | Transave, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1551962-A4 | MITOTIC KINESIN BINDING SITE | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1259235-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20070172475-A1 | Highly concentrated, liquid formulations of anti-egfr antibodies | MERCK PATENT GMBH (DE) | 2007-07-26 | — | — | US | disclosed |
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| CN-101005837-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2007-07-25 | — | — | CN | disclosed |
| WO-2007081572-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070161680-A1 | Substituted benzimidazoles and methods of their use | NOVARTIS AG | 2007-07-12 | — | — | US | disclosed |
| EP-1804821-A2 | HCV NS3-NS4A PROTEASE INHIBITION | Vertex Pharmaceuticals, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| CN-1997627-A | Histone deacetylase inhibitors | MERCK & CO INC (US) | 2007-07-11 | — | — | CN | disclosed |
| CN-1997626-A | Inhibitors of histone deacetylase | MERCK & CO INC (US) | 2007-07-11 | — | — | CN | disclosed |
| CN-1997625-A | Histone deacetylase inhibitors | MERCK & CO INC (US) | 2007-07-11 | — | — | CN | disclosed |
| US-20070149536-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070149553-A1 | Mitotic kinesin inhibitors | ARRINGTON KENNETH L | 2007-06-28 | — | — | US | disclosed |
| US-20070149594-A1 | Pyrrole derivatives | MERCK PATENT GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| EP-1558586-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1799669-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-7235580-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070142440-A1 | Pyridinamide derivatives as kinase inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142388-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070134660-A1 | Methods for identifying modulators of kinesin activity | ROSETTA INPHARMATICS LLC (US) | 2007-06-14 | — | — | US | disclosed |
| CN-1980662-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2007-06-13 | — | — | CN | disclosed |
| CN-1980911-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2007-06-13 | — | — | CN | disclosed |
| CN-1980663-A | Prodrugs of mitotic kinesin inhibitors | MERCK & CO INC (US) | 2007-06-13 | — | — | CN | disclosed |
| CN-1980938-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2007-06-13 | — | — | CN | disclosed |
| US-20070129356-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| WO-2007064658-A2 | SAFE AND EFFECTIVE METHODS OF ADMINISTERING THERAPEUTIC AGENTS | TRANSAVE, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1791969-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| CN-1976936-A | Tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2007-06-06 | — | — | CN | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061978-A1 | SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061880-A1 | SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070122350-A1 | Safe and effective methods of administering therapeutic agents | TRANSAVE, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070122411-A1 | Solid forms of anti-egfr antibodies | MERCK PATENT GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| WO-2007061764-A2 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070117824-A1 | Spirocyclic compounds | MERCK SHARP & DOHME LLC | 2007-05-24 | — | — | US | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| WO-2007059221-A2 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMACEUTICALS, INC (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007056263-A2 | METHODS OF TREATING CANCER WITH HIGH POTENCY LIPID-BASED PLATINUM COMPOUND FORMULATIONS ADMINISTERED INTRAVENOUSLY | TRANSAVE, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056236-A2 | METHODS OF TREATING CANCER WITH LIPID-BASED PLATINUM COMPOUND FORMULATIONS ADMINISTERED INTRAVENOUSLY | TRANSAVE, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056264-A2 | METHODS OF TREATING CANCER WITH HIGH POTENCY LIPID-BASED PLATINUM COMPOUND FORMULATIONS ADMINISTERED INTRAPERITONEALLY | TRANSAVE, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007055942-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112006-A1 | Amine derivatives | MERCK PATENT GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| EP-1784194-A1 | HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1784386-A2 | HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1784175-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20070105939-A1 | Mesylate salt of 5-(2-dimethylaminoethoxy)-1H-indole-2-carboxylic acid [3-(4-hydroxycarbamoylphenyl)prop-2-ynyl]amide | PHARMACYCLICS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| EP-1781287-A2 | THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENYZMES | Genentech, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1781286-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1781285-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007050380-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050401-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050383-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070099910-A1 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| CN-1953768-A | Highly concentrated liquid formulations of anti-EGFR antibodies | MERCK PATENT GMBH (DE) | 2007-04-25 | — | — | CN | disclosed |
| EP-1773326-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1773761-A1 | HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1542989-B1 | PROTEIN TYROSINE KINASE INHIBITORS | CRITICAL OUTCOME TECHNOLOGIES (CA) | 2007-04-18 | — | — | EP | disclosed |
| EP-1773815-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co. Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070082906-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-04-12 | — | — | US | disclosed |
| EP-1771167-A2 | HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| CN-1942470-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2007-04-04 | — | — | CN | disclosed |
| CN-1942465-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2007-04-04 | — | — | CN | disclosed |
| EP-1768955-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-04-04 | — | — | EP | disclosed |
| EP-1768956-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2007-04-04 | — | — | EP | disclosed |
| WO-2007035309-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| EP-1765334-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1765830-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| CN-1938282-A | Imidazole derivatives as tyrosine kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-03-28 | — | — | CN | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066606-A1 | Benzylbenzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| CN-1934066-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2007-03-21 | — | — | CN | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070060601-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-03-15 | — | — | US | disclosed |
| WO-2007030377-A1 | SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-03-15 | — | — | WO | disclosed |
| EP-1515949-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2007-03-14 | — | — | EP | disclosed |
| US-20070053869-A1 | Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents | WARNER-LAMBERT COMPANY LLC | 2007-03-08 | — | — | US | disclosed |
| WO-2007027560-A2 | FORMULATION AND METHOD FOR ENHANCEMENT OF GASTROINTESTINAL ABSORPTION OF PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2007-03-08 | — | — | WO | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
| EP-1517904-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2007019308-A2 | ILLUDIN ANALOGS USEFUL AS ANTICANCER AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-15 | — | — | WO | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| WO-2007015837-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-1656348-B1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARM INC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7169788-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2007011623-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| WO-2007011618-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021456-A1 | Aminobenzimidazole derivatives | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| CN-1902190-A | 2- (hetero) aryl-substituted tetrahydroquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-01-24 | — | — | CN | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| WO-2007008502-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| CN-1898215-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2007-01-17 | — | — | CN | disclosed |
| CN-1898249-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2007-01-17 | — | — | CN | disclosed |
| CN-1894276-A | HCV NS3-NS4A protease resistance mutants | VERTEX PHARMA (US) | 2007-01-10 | — | — | CN | disclosed |
| CN-1893951-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2007-01-10 | — | — | CN | disclosed |
| WO-2007002254-A2 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002248-A2 | MODIFIED MALONATE DERIVATIVES | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002258-A2 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1737861-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1737843-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060293358-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2006-12-28 | — | — | US | disclosed |
| CN-1886118-A | Solid forms of anti-EGFR antibodies | MERCK PATENT GMBH (DE) | 2006-12-27 | — | — | CN | disclosed |
| US-20060287248-A1 | Asymmetric dosing methods | SCHERING CORPORATION | 2006-12-21 | — | — | US | disclosed |
| US-20060287302-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-12-21 | — | — | US | disclosed |
| WO-2006135604-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135627-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| CN-1882571-A | Pyrrolderivate | MERCK PATENT GMBH (DE) | 2006-12-20 | — | — | CN | disclosed |
| EP-1635641-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060281688-A1 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| WO-2006131186-A1 | OXINDOLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2006-12-14 | — | — | WO | disclosed |
| US-20060281762-A1 | 1,3-Benzoxazolyl derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2006-12-14 | — | — | US | disclosed |
| US-20060281778-A1 | Compounds for inhibiting KSP Kinesin activity | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| EP-1730099-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060276404-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060276407-A1 | Methods of treating hepatitis C virus | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060275366-A1 | Controlled-release formulation | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| WO-2006130688-A2 | COMPOUNDS FOR INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060276514-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2006-12-07 | — | — | US | disclosed |
| WO-2006130686-A2 | HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130554-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130607-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130666-A2 | MEDICAMENTS AND METHODS COMBINING A HCV PROTEASE INHIBITOR AND AN AKR COMPETITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130687-A2 | LIVER/PLASMA CONCENTRATION RATIO FOR DOSING HEPATITIS C VIRUS PROTEASE INHIBITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130552-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060276406-A1 | Methods of treating hepatitis C virus | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| CN-1875023-A | Use of thienopyrimidines | MERCK PATENT GMBH (DE) | 2006-12-06 | — | — | CN | disclosed |
| US-20060270673-A1 | Inhibitors of akt activity | MERCK & CO., INC. (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1578724-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-11-29 | — | — | EP | disclosed |
| CN-1871232-A | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2006-11-29 | — | — | CN | disclosed |
| US-20060264468-A1 | Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | UNITED THERAPEUTICS CORPORATION | 2006-11-23 | — | — | US | disclosed |
| WO-2006124354-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006123182-A2 | CYCLOHEXYL SULPHONES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258699-A1 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION | 2006-11-16 | — | — | US | disclosed |
| US-20060252698-A1 | Compounds for inhibiting cathepsin activity | SCHERING CORPORATION | 2006-11-09 | — | — | US | disclosed |
| WO-2006115835-A2 | BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1556052-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006115833-A1 | BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES WITH CARBAMATE, UREA, AMIDE AND SULFONAMIDE SUBSTITUTIONS | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060246124-A1 | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally | PILKIEWICZ FRANK G | 2006-11-02 | — | — | US | disclosed |
| EP-1534268-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION | 2006-11-02 | — | — | US | disclosed |
| WO-2006113942-A2 | METHOD OF INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060241301-A1 | Urea derivatives and their use as tyrosinkinase inhibitors | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | US | disclosed |
| EP-1714676-A2 | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. Searle LLC. (US) | 2006-10-25 | — | — | EP | disclosed |
| US-7125888-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| WO-2006110638-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060234984-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. | 2006-10-19 | — | — | US | disclosed |
| WO-2006110390-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060223844-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-10-05 | — | — | US | disclosed |
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2006101780-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006101761-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| CN-1839128-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2006-09-27 | — | — | CN | disclosed |
| WO-2006098961-A2 | FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006098962-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
| CN-1835749-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2006-09-20 | — | — | CN | disclosed |
| CN-1835756-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2006-09-20 | — | — | CN | disclosed |
| CN-1835746-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2006-09-20 | — | — | CN | disclosed |
| US-7109204-B2 | controlling signal transduction; anticancer agents, antitumor agents, atherosclerosis, vision defects, antidiabetic agents, antiinflammatory agents | MERCK & CO., INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060205765-A1 | Inhibitors of akt activity | MERCK & CO., INC. (US) | 2006-09-14 | — | — | US | disclosed |
| WO-2006094604-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | MERCK PATENT GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
| EP-1509507-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-09-13 | — | — | EP | disclosed |
| CN-1829507-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2006-09-06 | — | — | CN | disclosed |
| EP-1697331-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1697381-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1696927-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| WO-2006091395-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| CN-1826317-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2006-08-30 | — | — | CN | disclosed |
| US-20060189630-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-08-24 | — | — | US | disclosed |
| US-20060189577-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-08-24 | — | — | US | disclosed |
| US-20060183755-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-08-17 | — | — | US | disclosed |
| WO-2006086255-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006086358-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006081230-A2 | 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006078598-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006078575-A2 | FLUORINATED AMINOALKYL-4-OXO-3,4-DIHYDROPYRIDO[3,4- D] PYRIMIDINES AS INHIBITORS OF MITOTIC KINESINS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006078574-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060167036-A1 | Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor | MERCK SHARP & DOHME CORP. | 2006-07-27 | — | — | US | disclosed |
| CN-1809536-A | Inhibitors of Akt activity | MERCK & CO INC (US) | 2006-07-26 | — | — | CN | disclosed |
| CN-1809354-A | Inhibitors of Akt activity | MERCK & CO INC (US) | 2006-07-26 | — | — | CN | disclosed |
| CN-1809540-A | Inhibitors of Akt activity | MERCK & CO INC (US) | 2006-07-26 | — | — | CN | disclosed |
| CN-1809351-A | Inhibitors of Akt activity | MERCK & CO INC (US) | 2006-07-26 | — | — | CN | disclosed |
| EP-1494675-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1496982-A4 | SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006074281-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006074207-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1678202-A1 | HCV NS3-NS4A PROTEASE RESISTANCE MUTANTS | Vertex Pharmaceuticals Incorporated (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20060142178-A1 | Method of treating cancer | BARNETT STANLEY F | 2006-06-29 | — | — | US | disclosed |
| US-20060142278-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-06-29 | — | — | US | disclosed |
| WO-2006068796-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006068933-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006069096-A1 | SILANOL DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| CN-1795175-A | Acetylene derivatives as inhibitors of histone deacetylase | AXYS PHARM INC (US) | 2006-06-28 | — | — | CN | disclosed |
| WO-2006065601-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060135594-A1 | Prodrugs of mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-06-22 | — | — | US | disclosed |
| WO-2006066183-A2 | NOVEL SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060134767-A1 | Mitotic kinesin binding site | MERCK & CO., INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006061638-A2 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2006-06-15 | — | — | WO | disclosed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | disclosed |
| US-7060705-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1664026-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006055352-A2 | METHODS OF TREATING CANCER WITH LIPID-BASED PLATINUM COMPOUND FORMULATIONS ADMINISTERED INTRAPERITONEALLY | TRANSAVE, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060111371-A1 | Protein tyrosine kinase inhibitors | DALTON CHEMICAL LABORATORIES, INC. (CA) | 2006-05-25 | — | — | US | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| EP-1658846-A1 | Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. SEARLE & CO. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060105997-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | disclosed |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | JACOB GARY S | 2006-05-18 | — | — | US | disclosed |
| EP-1656348-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1656133-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1656140-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1656146-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20060100191-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-05-11 | — | — | US | disclosed |
| EP-1496907-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1494676-A4 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1496897-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1496898-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060094671-A1 | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy | UNITHER VIROLOGY, LLC | 2006-05-04 | — | — | US | disclosed |
| EP-1651209-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| CN-1768031-A | hydroxamates as therapeutic agents | AXYS PHARM INC (US) | 2006-05-03 | — | — | CN | disclosed |
| EP-1651599-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1496906-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006040056-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006039488-A2 | HCV NS3-NS4A PROTEASE INHIBITION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006036395-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069105-A1 | Protein tyrosine kinase inhibitors | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2006-03-30 | — | — | US | disclosed |
| WO-2006031348-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060063942-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-03-23 | — | — | US | disclosed |
| WO-2006031607-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| EP-1635641-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1636182-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| US-20060058327-A1 | Kinesin spindle protein inhibitor; antiproliferative agents; anticancer agents; 4-(2,5-difluorophenyl)-N-3-fluoropyrrolidin-3-yl)-2-hydroxymethyl-2-phenyl-2,5-diphdro-1N-pyrrol-1-carboxamide | MERCK SHARP & DOHME CORP. | 2006-03-16 | — | — | US | disclosed |
| WO-2006026260-A1 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060052611-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-03-09 | — | — | US | disclosed |
| US-20060052416-A1 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | SQUARE 1 BANK | 2006-03-09 | — | — | US | disclosed |
| EP-1631548-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2006023083-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006023440-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1629284-A2 | METHODS FOR IDENTIFYING MODULATORS OF KINESIN ACTIVITY | Rosetta Inpharmatics LLC. (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2006020767-A2 | THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENZYMES | GENENTECH, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020004-A2 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006017215-A2 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006017216-A1 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1622616-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20060025426-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
| EP-1620411-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1620095-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1458726-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2006007496-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006007491-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006007501-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006005941-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006005955-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006007497-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| EP-1404672-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1492487-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1465896-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1481077-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1463733-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1551812-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1611088-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050288294-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-12-29 | — | — | US | disclosed |
| WO-2005118584-A2 | SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER | AXYS PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267153-A1 | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | MUELLER RICHARD A | 2005-12-01 | — | — | US | disclosed |
| US-20050261496-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2005-11-24 | — | — | US | disclosed |
| EP-1503757-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1218376-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1515949-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6960590-B2 | Orally active salts with tyrosine kinase activity | MERCK & CO. INC. (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2005100356-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005100344-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050239815-A1 | Tyrosine kinase inhibitors | KIM ANNETTE J | 2005-10-27 | — | — | US | disclosed |
| US-6958340-B2 | such as N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine; treating breast cancer; use in combination with estrogen receptor modulators such as tamoxifen and raloxifene | MERCK & CO., INC. (US) | 2005-10-25 | — | — | US | disclosed |
| WO-2005097770-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050234080-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J | 2005-10-20 | — | — | US | disclosed |
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | disclosed |
| US-20050227988-A1 | compounds capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; gliomas, meningomas, cancers, Hodgkin's disease, retinal vascularization; core structure that comprises a benzazocine moiety | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| US-20050228003-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| CN-1679568-A | Use of n-substituted-1,5-di deoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | SEARLE & CO (US) | 2005-10-12 | — | — | CN | disclosed |
| WO-2005092011-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| US-20050222155-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-10-06 | — | — | US | disclosed |
| EP-1581497-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1578724-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| CN-1674906-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2005-09-28 | — | — | CN | disclosed |
| US-20050203110-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050197299-A1 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-08 | — | — | US | disclosed |
| EP-1328519-B1 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050182256-A1 | 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; antiproliferative | MERCK & CO., INC. | 2005-08-18 | — | — | US | disclosed |
| EP-1515724-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050176753-A1 | controlling signal transduction; anticancer agents; antitumor agnets; atherosclerosis; vision defects; antidiabetic agents; antiinflammatory agents | MERCK SHARP & DOHME CORP. | 2005-08-11 | — | — | US | disclosed |
| US-20050176737-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-08-11 | — | — | US | disclosed |
| US-20050176776-A1 | kINESIN SPINDLE PROTEIN INHIBITOR; ANTIPROLIFERATIVE AGENTS; ANTICANCER AGENTS; 4-(2,5-DIFLUORPHENYL)-N-3-FLUOROPYRROLIDIN-3-YL)-2-HYDROXYMETHYL-2-PHENYL-2,5 -DIHYDROXY-1N-PYRROL-1-CARBOXAMIDE | MERCK SHARP & DOHME CORP. | 2005-08-11 | — | — | US | disclosed |
| US-6927293-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-08-09 | — | — | US | disclosed |
| US-20050171122-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-08-04 | — | — | US | disclosed |
| EP-1558609-A2 | KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1558586-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| CN-1213045-C | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2005-08-03 | — | — | CN | disclosed |
| EP-1556052-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005065183-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050159422-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-07-21 | — | — | US | disclosed |
| EP-1551962-A2 | MITOTIC KINESIN BINDING SITE | Merck & Co., Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1551824-A1 | PROTEIN TYROSINE KINASE INHIBITORS | Danter, Wayne R. (CA) | 2005-07-13 | — | — | EP | disclosed |
| EP-1551812-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005060654-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061518-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050136400-A1 | NS3-NS4A protease resistance mutants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| EP-1542989-A1 | PROTEIN TYROSINE KINASE INHIBITORS | Danter, Wayne R. (CA) | 2005-06-22 | — | — | EP | disclosed |
| US-20050131018-A1 | Acetylene derivatives as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-16 | — | — | US | disclosed |
| US-20050130977-A1 | 2,3-diphenylquinoxaline derivatives which inhibit a serine, threonine protein kinase; cancer | MERCK & CO., INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | PHARMACIA CORPORATION | 2005-06-02 | — | — | US | disclosed |
| US-20050119484-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-06-02 | — | — | US | disclosed |
| WO-2004011456-A9 | PROTEIN TYROSINE KINASE INHIBITORS | DANTER WAYNE R (CA) | 2005-06-02 | — | — | WO | disclosed |
| EP-1534695-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113577-A1 | Solid forms of slats with tyrosine kinase activity | KARKI SHYAM B (US) | 2005-05-26 | — | — | US | disclosed |
| CN-1202824-C | Use of N-substituted 1, 5-dideoxy-1, 5-imino-D-glucitol compounds for the treatment of hepatitis virus infections | SEARLE & CO (US) | 2005-05-25 | — | — | CN | disclosed |
| US-20050107404-A1 | Mitotic kinesin inhibitors | FRALEY MARK E (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2005042570-A1 | HCV NS3-NS4A PROTEASE RESISTANCE MUTANTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096344-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2005-05-05 | — | — | US | disclosed |
| US-6875767-B2 | (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1517904-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-6872724-B2 | Polymorphs with tyrosine kinase activity | MERCK & CO., INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1515724-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1515949-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1226119-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2005018638-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019206-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019205-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018547-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019174-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1509507-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20050043357-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-02-24 | — | — | US | disclosed |
| WO-2005017190-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038074-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J (US) | 2005-02-17 | — | — | US | disclosed |
| EP-1444209-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20050032817-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 3-benzyl-2-(1-{(4-bromobenzyl)[2-(dimethylamino)ethyl]amino}propyl)furo[2,3-d]pyrimidin-4(3H)-one; antiproliferative and -carcinogenic agents; side effects reduction; cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung | MERCK SHARP & DOHME CORP. | 2005-02-10 | — | — | US | disclosed |
| EP-1503757-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| WO-2005009373-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026929-A1 | Novel phenyl derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009957-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1496981-A2 | METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1496896-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1496897-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1496907-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1496906-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1496898-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1494676-A1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| EP-1492487-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004112699-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-1226136-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040259826-A1 | Mitotic kinesin inhibitors | MERCK & CO., INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004111193-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004109290-A2 | METHODS FOR IDENTIFYING MODULATORS OF KINESIN ACTIVITY | ROSETTA INPHARMATICS LLC (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-1328519-A4 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040242637-A1 | Tyrosine kinase inhibitors | HARTMAN GEORGE D (US) | 2004-12-02 | — | — | US | disclosed |
| EP-1481077-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040235826-A1 | Tyrosine kinase ihnibitors | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
| US-20040235867-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2004-11-25 | — | — | US | disclosed |
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
| WO-2004096135-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096129-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096131-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096130-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220216-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2004-11-04 | — | — | US | disclosed |
| US-20040220201-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220182-A1 | Chromenone derivatives | MERCK PATENT GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| EP-1259236-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-6809083-B1 | INHIBITING REPLICATION AND SECRETION; REDUCED TOXICITY | UNITHER VIROLOGY, LLC | 2004-10-26 | — | — | US | disclosed |
| WO-2004087050-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-1465896-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1463733-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040192725-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040192926-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2004-09-30 | — | — | US | disclosed |
| EP-1458726-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6794393-B1 | inhibitors of VEGF; angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases; 1H-indole compounds having a fused nitrogen heterocycle amide in the 2-position | MERCK & CO., INC. | 2004-09-21 | — | — | US | disclosed |
| US-20040181066-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2004-09-16 | — | — | US | disclosed |
| US-20040176440-A1 | 2-Benzoylchromone derivatives | MERCK PATENT GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| US-20040171630-A1 | both receptor-type and non-receptor type tyrosine kinases; to treat angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, | KIM YUNTAE (US) | 2004-09-02 | — | — | US | disclosed |
| CN-1523980-A | Pharmaceutical formulations containing an active dispersed in a matrix | ��̹��ҽҩ��˾ | 2004-08-25 | — | — | CN | disclosed |
| EP-1444209-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| WO-2004058148-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058700-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040138464-A1 | 2-Oxadiazolechromone derivatives | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052286-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052315-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-6747149-B2 | ADMINISTERING VIRICIDES SUCH AS N-NONENYL GLUCOSAMINE, AND OPTIONALLY WITH MIXTURES OF NUCLEOSIDES, NUCLEOTIDES, IMMUNOMODULATORS OR IMMUNOSTIMULANTS FOR PROPHYLAXIS VIRAL DISEASES | G. D. SEARLE & CO. | 2004-06-08 | — | — | US | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| WO-2004041164-A2 | KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004041162-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004039774-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004037171-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004033446-A1 | PROTEIN TYROSINE KINASE INHIBITORS | DANTER WAYNE R (CA) | 2004-04-22 | — | — | WO | disclosed |
| EP-1404672-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| WO-2004014882-A2 | PROTEASOME INHIBITORS : PEPTIDE DERIVATIVES HAVING C-TERMINAL HETEROARYL GROUPS | AXYS PHARMACEUTICALS (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014851-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| US-6689759-B1 | COMBINED WITH NUCLEOSIDE AND/OR NUCLEOTIDE ANTIVIRAL AGENTS AND IMMUNOSTIMULANTS | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | disclosed |
| US-20040023978-A1 | Active salt forms with tyrosine kinase activity | REN YU | 2004-02-05 | — | — | US | disclosed |
| US-20040023981-A1 | Salt forms with tyrosine kinase activity | REN YU (US) | 2004-02-05 | — | — | US | disclosed |
| WO-2004011456-A1 | PROTEIN TYROSINE KINASE INHIBITORS | DANTER WAYNE R (CA) | 2004-02-05 | — | — | WO | disclosed |
| US-20040023980-A1 | Polymorphs with tyrosine kinase activity | MERCK SHARP & DOHME CORP. | 2004-02-05 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| WO-2004004727-A1 | 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004004652-A2 | MITOTIC KINESIN BINDING SITE | MERCK & CO., INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20040002501-A1 | Orally active salts with tyrosine kinase activity | FRALEY MARK E (US) | 2004-01-01 | — | — | US | disclosed |
| WO-2003106417-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003105855-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003099211-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-6656942-B2 | For therapy of diseases such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals | MERCK & CO., INC. | 2003-12-02 | — | — | US | disclosed |
| WO-2003092595-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003090680-A2 | NOVEL PHENYL DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-1496982-A2 | SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-10-30 | — | — | EP | disclosed |
| WO-2003088900-A2 | SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003086279-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003086403-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003086395-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003086314-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003086315-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1494675-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2003-10-23 | — | — | EP | disclosed |
| WO-2003086404-A1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003086394-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| CN-1451014-A | Peptidomimetic protease inhibitors | LILLY CO ELI (US) | 2003-10-22 | — | — | CN | disclosed |
| WO-2003084473-A2 | METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003079973-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| EP-1341540-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-1328519-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-07-23 | — | — | EP | disclosed |
| US-6586423-B2 | 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-6586424-B2 | Anticancer agents; anticholesterol agents | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1320540-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2003049679-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003049678-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003049527-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050122-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050064-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030100567-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003039460-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003037252-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003035619-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035616-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035615-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035614-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| CN-1409708-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-04-09 | — | — | CN | disclosed |
| EP-1226119-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6544988-B1 | Pyrazolo(1,5-a)pyrimidin-6-yl)-1H-pyridin-2-one derivatives | MERCK & CO., INC. | 2003-04-08 | — | — | US | disclosed |
| US-6545021-B1 | Including ether and ester derivatives as well as N-carbonyl derivatives | G.D. SEARLE & CO. | 2003-04-08 | — | — | US | disclosed |
| US-20030064996-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| WO-2003024931-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024969-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003020276-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020699-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003015778-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016572-A1 | OLIGONUCLEOTIDE THERAPEUTICS FOR TREATING HEPATITIS C VIRUS INFECTIONS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003015717-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003011838-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011837-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011836-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003009852-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-06 | — | — | WO | disclosed |
| US-6515028-B1 | Used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| CN-1390215-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-01-08 | — | — | CN | disclosed |
| WO-2003000687-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002102783-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| EP-1259236-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1218376-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6479512-B1 | TO TREAT TYROSINE KINASE-DEPENDENT DISEASES AND CONDITIONS, SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, ETC. | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020147203-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| EP-1226119-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1226136-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6420382-B2 | QUINOLIN-2-ONE DERIVATIVES TO TREAT ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY AND INFLAMMATORY DISEASES | MERCK & CO., INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1218376-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | MERCK & CO., INC. | 2002-06-13 | — | — | US | disclosed |
| WO-2002045652-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| EP-1161433-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002032861-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002018369-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| CN-1328457-A | Use of N-substituted 1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | SEARLE & CO (US) | 2001-12-26 | — | — | CN | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| EP-1161433-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2001-12-12 | — | — | EP | disclosed |
| US-20010047007-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2001-11-29 | — | — | US | disclosed |
| US-20010044451-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2001-11-22 | — | — | US | disclosed |
| US-6313138-B1 | FOR THERAPY OF ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES IN MAMMALS | MERCK & CO., INC. | 2001-11-06 | — | — | US | disclosed |
| US-6306874-B1 | ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2001062252-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-6245759-B1 | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; ANTICARCINOGENIC AND ANTITUMOR AGENTS; ATHEROSCLEROSIS, ANGIOGENESIS INHIBITORS | MERCK & CO., INC. | 2001-06-12 | — | — | US | disclosed |
| WO-2001028993-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029025-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001017995-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000053605-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| US-4146720-A | RODENTICIDES AND ANTITUMOR AGENTS | LABORATORIOS MADE, S.A. (ES) | 1979-03-27 | — | — | US | disclosed |
| US-4146720-A | RODENTICIDES AND ANTITUMOR AGENTS | LABORATORIOS MADE, S.A. (ES) | 1979-03-27 | — | — | US | disclosed |